











AN ANALYSIS OF 
CLINICAL AND LABORATORY DATA 
OF PATIENTS AT THE RED CROSS 
CHILDREN'S HOSPITAL. 
INVESTIGATOR: 
Dr GTM RIORDAN 
M.B.Ch.B. F.C.P. (S.A.) Paed. 
SUPERVISOR: 
Professor PM LEARY 
A dissertation presented in part fulfilment of requirements for the degree 
M.Med. (Paed) at the University of Cape Town 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 











I C: 1 '-t-t/tN etcR.o.<JNh b d l h h k h. h h. , ............................... , ere y ec are t at t e wor on w 1c t 1s 
thesis is based is my original work (except where acknowledgements 
indicate otherwise) and that neither the whole work nor any part of it has 
been, is being, or is to be submitted for another degree in this or any other 
University. 
I empower the University to reproduce for the purpose of research either 




Research today is seldom the result of efforts by the principal author alone. 
There are those named and often countless unnamed supporters without 
whose contributions a work may not reach completion. 
I would like to gratefully thank: 
my supervisor, Professor PM Leary, for his encouragement 
the trustees of the KM Browse Scholarship for supporting the study 
Drs P Owen and A Marinaki, from the Department of Chemical Pathology, 
for fibroblast and genetic studies 
Drs A Westwood, A Thomson and L Reynolds, for contributing patients to 
the study 
Dr P Kirby, for reviewing the histopathology 
consultants and registrars in Ophthalmology, for formal fundoscopy 
EEG laboratory, audiology, A5 nursing and secretarial staff all of whom 
helped to keep the wheels rolling 
last but not least, those without whom there would have been no study, the 
patients and their parents 
finally, those unnamed whose efforts directly or indirectly helped to make 




3. LITERATURE REVIEW 




3.2 Clinical Aspects of the Disorders 
3.3 Radiology of the Disorders 
3.4 Histopathology 
3.5 Biochemical Studies 
3.6 Mitochondrial Genetics 








The term "mitochondrial encephalomyopathy" encompasses a broad 
spectrum of clinical pathology related to mitochondrial dysfunction. In this 
review a brief historical account of developments in the field will be given, 
concentrating on the clinical aspects. A detailed account of advances in the 
understanding of mitochondrial molecular biology is beyond the scope of 
this text and readers are referred to authoritative reviews (1). 
Mitochondrial disorders have gained increasing importance in clinical 
medicine in recent years. They not only deserve consideration in the 
differential diagnosis of many neuromuscular problems, but are known to 
be responsible for certain forms of cardiovascular, renal and hepatic 
disease, and can be linked to diabetes mellitus in some families. The role 
of mitochondrial dysfunction in the aging process is currently being 
explored. 
The diagnosis is often overlooked as there are few specific clinical and 
biochemical tests accessible to the average clinician. The incidence of these 
disorders remains unknown and they may be far more common than 
originally thought. 
The fundamental defect underlying mitochondrial disorders is an inadequate 
production of ATP to meet cellular energy demands. This may be masked 
by the presence of heteroplasmy, the coexistence of normal and mutated 
mitochondrial DNA (mtDNA) within a single cell. Thus the condition may 
remain occult unless subjected to stress in the form of exercise, 
carbohydrate loading or infection. It is probable that many carriers with 
minor defects remain asymptomatic, even under these conditions. 
---oOo---
MITOCHONDRIA 
Mitochondria are intracellular organelles responsible primarily for the 
efficient production of adenosine triphosphate (ATP) to meet cellular 
energy demands. Although mitochondrial deoxyribonucleic acid (mtDNA) 
was discovered over thirty years ago (2), its relevance to human pathology 
has only recently been appreciated with the advent of new molecular 
techniques. 
Mitochondrial DNA is unique in that it is inherited exclusively from the 
oocyte, resulting in maternal transmission of pathogenic mutations. 
Structurally, mitochondrial DNA is a small, circular double-stranded 
molecule of 16,5 kilobase (kb). Its genetic code differs from the nuclear 
code, which has implications for future gene therapy. This reflects the 
probable bacterial origins of mitochondria. The genome has been entirely 
sequenced and codes for 13 proteins, two ribosomal ribonucleic acids 
(rRNAs) and 22 transfer RNAs (tRNAs). The protein genes all code for 
subunits of the respiratory chain: 7 subunits of nicotinamide adenine 
dinucleotide(reduced) dehydrogenase (NADH), 3 of cytochrome c oxidase, 
2 of A TPase and 1 of cytochrome b. 
There are on average between 2 and 10 copies of the mitochondrial 
genome in each mitochondrion and many hundred mitochondria in each 
cell. Thus each cell has thousands of copies of the mitochondrial genome. 
Normally these are identical in every cell, a situation known as 
homoplasmy. If a mutation exists it may be homoplasmic and involve all 
genomes, or, more commonly, may coexist with normal wild type DNA in 
a state of heteroplasmy. The degree of heteroplasmy may vary from tissue 
to tissue as a result of random distribution of mitochondria during cell 
division and possibly also as a consequence of a selective advantage of one 
type over another within tissues. 
This random distribution explains the phenotypic variance which occurs 
within individuals expressing the same mutation. A pathogenic mutation 
will become clinically expressed only if present in sufficient proportion to 
wild type mtDNA to reduce nett energy metabolism within a particular 
tissue. This phenomenon is known as the threshold effect. Each tissue 
varies in susceptibility depending on its metabolic demands. As little as 10 
percent of wild type mtDNA may offer protection from cellular 
dysfunction. 
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With the recent discovery of many disorders caused by mtDNA mutations, 
it has sometimes been dubbed the "25th chromosome". Despite this 
increase in knowledge, many questions remain unanswered. 
Explanations for the high mutation rate in mtDNA have been its close 
proximity to free radicals generated by oxidative phosphorylation, its lack 
of protective histones and its limited DNA repair mechanisms (3). Deleted 
mtDNA may have a replicative advantage owing to its smaller size. 
MtDNA deletions are responsible for the Kearns Sayre Syndrome (KSS): 
the other two commonly identified clinical syndromes, mitochondrial 
myopathy, encephalopathy, lactic acidosis and stroke-like episodes 
(MELAS) and myoclonus, epilepsy and ragged-red fibres, (MERRF), are 
caused by point mutations. The point mutations in both cases affect transfer 
RNA genes. A single base pair is substituted. In MERRF the transition is at 
base pair (bp) 8344 where guanine is substituted for adenine (A8344G) in 
the tRNA lysine gene. In MELAS there is a similar substitution at bp 3243 
in the tRNA leucine gene. Point mutations in tRNA can cause multiple 
defects depending on the significance of the substitution on the function of 
the encoded protein. 
---oOo---
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MITOCHONDRIAL ENCEPHALOMYOPA THIES: 
A REVIEW OF THE LITERATURE 
HISTORICAL PERSPECTIVE 
Progress in the identification of clinical syndromes caused by mitochondrial 
mutations has gained increasing momentum in recent years. Stimulus to 
research in this direction started in 1959 with the publication of an article in 
Nature by Ernster, lkkos and Luft describing the usefulness in clinical 
research of studies of mitochondrial enzyme activities (4). This was 
followed in 1962 by Luft' s report (5) of a 35 year old woman with severe 
non-thyroidal hypermetabolism due to defective mitochondrial respiratory 
control. 
In 1972, Olson et al(6) reported 7 cases of chronic progressive external 
ophthalmoplegia in whom skeletal muscle biopsy specimens showed red 
accumulations in the subsarcolemmal and intermyofibrillar regions with the 
modified Gomori trichrome stain. These irregularly shaped fibres were 
called "ragged-red". Oxidative stains and electron microscopy identified 
aggregates of abnormal mitochondria in these areas, mainly within Type 1 
fibres. These histological findings gave new insight into the aetiology of the 
syndrome described by Kearns and Sayre (7) in 1958: an association of 
progressive ophthalmoplegia with retinal pigmentation, cardiac conduction 
defects and ataxia. Previous descriptions of this syndrome had been 
recorded, the first attributed to Von Graef in 1856. In 1968 Drachman (8) 
coined the term "ophthalmoplegia plus" to include all syndromes combining 
chronic progressive ophthalmoplegia with other forms of neuronal 
degeneration. 
The 1970s brought confirmation of mitochondrial dysfunction with the 
identification of respiratory chain defects by a growing number of 
researchers (9, 10, 11). The clinical presentations of their patients covered a 
broad spectrum which included ophthalmoplegia, weakness, ataxia, 
deafness and growth failure, often accompanied by lactic acidosis. 
Maternal inheritance was suggested as a mechanism for Leber's Hereditary 
Optic Neuropathy (LHON) (12), a form of neuroretinal degeneration 
occurring in adolescent males. 
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Tsairis and coworkers (13) described a family with myoclonus epilepsy 
associated with ragged-red fibres in 1973. This was the first report of this 
combination of findings. In 1977, Shapira et al(14) proposed the term 
"mitochondrial encephalomyopathy" to describe complex multisystem 
diseases associated with structurally or functionally abnormal mitochondria 
in brain or muscle. 
Publication in the same year of an article entitled "Lumping or Splitting? 
"Ophthalmoplegia Plus" or Kearns-Sayre Syndrome?" by Berenberg et al 
(15) provoked debate. The authors reviewed the clinical, biochemical and 
histological data of 5 new patients with ophthalmoplegia, retinal 
degeneration and heart block as well as 30 from the literature. They 
concluded that the findings in KSS were specific enough to warrant its 
classification as an independent entity, separate from the broad group of 
chronic ophthalmoplegias. Interestingly, persistent viral infection was 
considered a likely pathogenetic mechanism for KSS at that time. 
This was followed in 1980 by Fukuhara's paper on myoclonus epilepsy 
associated with ragged-red fibres (MERRF)(16). In this he described 2 
patients with myoclonus, convulsions, mental deterioration, cerebellar signs 
and muscular atrophy who had ragged-red fibres on muscle biopsy. The 
clinical findings were compared with those of other neurological disorders 
known to have mitochondrial structural abnormalities: Kearns-Sayre (Shy) 
Syndrome, Leigh encephalopathy, familial poliodystrophy (Alpers 
Syndrome) and Trichopoliodystrophy (Menkes disease). Genetic studies 
have since confirmed the existence of MERRF as a specific syndrome. 
Later that year DiMauro (17) published a report on an infant who died at 3 
months following progressive muscle weakness. This was associated with 
Fanconi syndrome and lactic acidosis. Although there were no ragged-red 
fibres, mitochondrial abnormalities were present on muscle biopsy and 
cytochrome c oxidase(cox) activity was less than 10% of normal in muscle 
and was reduced in kidney. 
In 1984, Pavlakis and coworkers (18) reported 2 cases of mitochondrial 
myopathy, encephalopathy, lactic acidosis and stroke-like episodes, a 
syndrome for which they proposed the acronym "MELAS". The first 
patient had delayed motor and language development at 3 years, short 
stature at 8 years and sensorineural deafness at 14 years. At 15 he had 2 
generalized seizures with residual weakness and sensory loss in the left 
arm. Computed axial tomography (CT) showed a right frontoparietal 
lucency. At 16 he was admitted to hospital with right hand weakness, 
confusion and aggression. Cerebrospinal fluid(CSF) protein was elevated at 
0, 76g/l. Bilateral non-enhancing parietal lucencies were present on CT scan 
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and cerebral angiography was normal. Resolution of the hemiparesis 
occurred within 2 weeks but 2 months later he presented with hallucinations 
and speech abnormalities. Again parietal lucencies were noted, arterial 
lactate was 2,7 millimoles/Litre (mM/L), CSF lactate 4,9 mM/L and 
ragged-red fibres(RRF) were seen on muscle biopsy. 
The other patient had normal early development but there was a fall off in 
growth and school performance by 9 years when he presented with a right 
hemiparesis. This resolved over 4 weeks but 2 months later he developed 
sudden blindness accompanied by a generalised seizure. Bioccipital 
lucencies were seen on CT scan. The blindness improved but a left 
hemiparesis occurred 12 hours after a cerebral angiogram which had 
demonstrated right extracranial carotid occlusion. Lucencies were then 
present in the right basal ganglia and both occipital lobes. Investigation at 
14 years showed an arterial lactate of 4mM/L, CSF lactate of 6, 1 mM/L 
and ragged-red fibres. 
Nine other children included in this study had similar symptoms with an 
onset between 3 and 11 years. On the basis of the similarities in clinical and 
laboratory findings in these patients, a new subgroup of mitochondrial 
diseases was proposed, the MELAS syndrome. 
Thus by the mid 1980s 5 distinct clinical entities caused by mitochondrial 
dysfunction had been described; MELAS, MERRF, KSS, LHON and fatal 
infantile mitochondrial myopathy due to cytochrome c oxidase deficiency. 
This was in addition to the conditions mentioned by Fukuhara; Leigh, 
Alpers and Menkes syndromes. The number of reported cases grew steadily 
and it was recognised that there is a considerable degree of clinical overlap 
between syndromes. What followed was rapid progress in unravelling the 
genetics of these disorders facilitated by the advances in molecular biology 
which are revolutionising medical research in the 1990s. 
The first documentation of a mtDNA point mutation was achieved by 
Wallace and coworkers (19) in 1988 in 9 of 11 families with LHON. This 
mutation resulted in the substitution of arginine for histidine in subunit 4 of 
complex 1 of the respiratory chain. Since then a number of other point 
mutations have been linked to LHON. 
The next report of a mutation involving a structural gene was one affecting 
mitochondrial ATP synthetase (20). This occurred in association with a new 
clinical syndrome characterised by developmental delay, retm1t1s 
pigmentosa, ataxia and sensory neuropathy. This disorder has been given 
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the acronym NARP. When greater than 90% of the mtDNA is affected by 
the NARP mutation a fatal infantile neuropathy with the features of Leigh 
syndrome occurs (21). 
An adenine to guanine point mutation at bp 8344 in the tRNA lysine gene 
was reported in 1988 by Wallace et al (22). This mutation has shown 
consistent correlation with the MERRF phenotype and in addition has been 
reported in association with Leigh Syndrome (23), myopathy or myoclonus 
with truncal lipomas and proximal myopathy (24). A second mutation at bp 
8356 in the same tRNA lysine gene has been reported (25). 
In 1990 an article in Nature by Goto and coworkers (26) described a 
mutation in the mitochondrial tRNA leucine gene, at bp 3243 and linked it 
to MELAS syndrome. A second mutation at bp 3271 on the same tRNA 
gene has since been reported (27). Both these point mutations have been 
shown to be maternally inherited. There is wider phenotypic variation with 
the tRNA leucine mutation than with the MERRF mutation, with some 
patients displaying myoclonus or ataxia in addition to features of MELAS. 
In 1992, Reardon (28) reported a family with deafness, diabetes with low 
insulin levels and cardiomyopathy as the cardinal findings and a pattern of 
maternal inheritance. A bp A3243G mutation was identified by polymerase 
chain reaction (PCR) in the blood of all the diabetic patients tested as well 
as all offspring of female patients. No family members had neurological 
signs other than deafness. The relationship between this mutation and 
diabetes is not yet clear but diabetes and deafness are relatively common 
findings in relatives of patients with MELAS. 
New mutations continue to be identified. Clarification of the relationship 
between mutation, biochemical defect and phenotype remains a challenge 
for the future. 
CLASSIFICATION OF MITOCHONDRIAL DISORDERS 
Classifications require regular updating. The biochemical classification of 
DiMauro (29) has been consistently useful. 
BIOCHEMICAL CLASSIFICATION OF MITOCHONDRIAL MYOPATHIES 
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I.DEFECTS OF TRANSPORT 
a)Carnitine palmitoyl transferase (CPT) deficiency 
b )Carnitine deficiency 
c)Defect of FAD uptake 
2.DEFECTS OF SUBSTRATE UTILISATION 
a)Pyruvate carboxylase deficiency 
b)Pyruvate dehydrogenase complex deficiency 
c)Defects of beta oxidation 
3.DEFECTS OF THE KREBS CYCLE 
a)Fumarase deficiency 
b)Alpha ketoglutarate dehydrogenase deficiency 
4.DEFECTS OF OXIDATION PHOSPHORYLATION COUPLING 
a)Luft's syndrome 
5.DEFECTS OF THE RESPIRATORY CHAIN 
a)Complex I deficiency 
b)Complex II deficiency 
c)Complex III deficiency 
d)Complex IV deficiency 
e)Complex V deficiency 
f)Combined defects of respiratory chain components 
An additional genetic classification has been proposed by the same author. 
GENETIC CLASSIFICATION 
I.DEFECTS OF MITOCHONDRIAL DNA 
a)Point mutations (maternal inheritance) 
b)Deletions and duplications(sporadic) 
2.DEFECTS OF NUCLEAR DNA (Mendelian Inheritance) 
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a)Defects in genes encoding mitochondrial proteins 
b)Defects of mitochondrial protein importation 
c)Defects of intergenomic communication 
CLINICAL ASPECTS 
This section will deal with aspects of clinical symptomatology relevant to 
the research study. Numerous clinical studies are now available for 
comparison but only a few of them concentrate on paediatric cases. Some 
of the more lethal conditions are seen virtually exclusively in neonatal or 
paediatric patients, but these are fortunately uncommon. The remainder 
may present at almost any age, the more severe defects tending to be 
diagnosed earlier. As pathology in mitochondrial disorders often evolves 
over many years, the diagnosis may not be evident in initial stages. 
Apart from Luft' s disease, which is very rare, the Kearns-Sayre syndrome 
and LHON were the earliest described clinical syndromes relating to 
mitochondrial dysfunction. LHON does not tend to present before 
adolescence and will therefore not be covered. MERRF, MELAS, Leigh, 
Alpers and PDH deficiency will be covered briefly. 
KEARNS-SAYRE SYNDROME 
KSS is a clinical syndrome with childhood onset, retinitis pigmentosa (RP) 
and chronic progressive ophthalmoplegia. In addition, one of the following 
is present: heart block, ataxia or an elevated CSF protein. Of Berenberg's 
30 cases(15), all had onset before the age of 20 years, the youngest at three 
years. Ophthalmoplegia, preceded usually by ptosis, was the presenting 
symptom in 26 and pigmentary degeneration in 3. All had a degree of heart 
block although this was latent for prolonged periods in some patients. In 
addition to the cardinal features a number had short stature, impaired 
intellect, deafness, vestibular dysfunction, delayed puberty or weakness. 
Facial, palatal and neck weakness were also found as was a positive 
Babinski sign. CSF protein was elevated in 24/25 patients, the highest 
being 4g/l. 
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Ophthalmoplegia did not cause diplopia and was usually asymptomatic until 
eye movements were all markedly limited. Ptosis was asymmetrical in some 
patients. Pupillary responses were normal except for one case with a 
sluggish light reflex. 
Retinal pigmentation was atypical with diffuse, fine stippling centrally and 
little effect on vision. 40 % of patients had mild reduction in visual acuity or 
night blindness. 
Retinopathy has been studied intensively by Mullie and coworkers (30). In 
1985, they looked at 61 patients with mitochondrial myopathy, some of 
whom had KSS. 22 had a "salt and pepper" retinopathy with severe visual 
loss in 2. Two had atypical RP and 2 had loss of retinal pigmentary 
epithelium. These four were the most impaired. Electroretinogram (ERG) 
done in 11 patients with clinical retinopathy was abnormal in all, with 
reduced rod and cone response in 8. 
Conduction blocks in Berenberg' s patients ranged from prolonged 
interventricular conduction time to complete heart block and were the cause 
of death in 7 patients. The longest interval between the appearance of 
ophthalmoplegia and recognition of heart block was 36 years. Conduction 
disturbances increased in severity with time and once symptomatic required 
pacing. CSF protein may be used as a guide to which patients with 
progressive ophthalmoplegia require regular cardiac assessment. 
Although no patient had seizures, nonfocal abnormalities on 
electroencephalogram (EEG) were found in 20/24 cases. 
Seven of 9 patients had ragged-red fibres on muscle biopsy, 3 with normal 
electromyograms(EMG). Eight of 8 had abnormal mitochondria on 
electron microscopy(EM). 
Postmortem examination done on 5 patients showed coarse vacuolisation 
within deep white matter, brainstem and spinal cord. 
No family had more than one case of KSS indicating sporadic inheritance. 
MYOCLONUS, EPILEPSY AND RAGGED-RED FIBRES (MERRF) 
Clinical variation in this group is greater than in KSS. Previous reports 
consisted mainly of small group and family studies. 
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Fukuhara's original description was of 2 cases. The first, a 21 year old 
woman presented at 16 years with myoclonus and dysarthria. She was 
found to have coarse horizontal nystagmus, saccadic eye movements, 
scanning speech, intention tremor and ataxia. Tendon reflexes were absent, 
Babinski sign positive unilaterally and Romberg sign positive. She had pes 
cavus. She developed generalised seizures soon after presentation. 
Muscle fibres showed variable size and ragged-red staining. 
Her mother and brother both had abnormalities on EEG. The brother had a 
tremor of the hands and neck. 
The second patient was a male who had developed dysarthria and 
myoclonus by 13 years. At 21 years he was found to have optic atrophy, 
marked horizontal nystagmus, scanning speech, ataxia and intention tremor. 
In addition myoclonus and generalized weakness were present with absent 
reflexes and positive Romberg sign. His muscle biopsy showed ragged-red 
fibres in 10% of fibres with moderate atrophy and interstitial fibrosis. He 
died a year later and autopsy revealed neuronal degeneration and gliosis in 
the subthalamic nucleus, striatum, globus pallidus, red nucleus and superior 
colliculus. These changes extended to the superior and inferior cerebellar 
peduncles, the dentate nucleus, the posterior columns of the spinal cord, the 
spinocerebellar tracts and anterior and posterior nerve roots. 
On the basis of his findings, Fukuhara suggested that MERRF be 
recognised as a separate entity. 
Rosing (31) described a large family in 1983 who had features similar to 
those of Fukuhara's patients. Some members were also deaf. They had 
spasticity with brisk reflexes in contrast to the others mentioned. 
Inheritance was clearly maternal but not X-linked. 
Berkovic et al (32) examined 84 cases of progressive myoclonic epilepsy 
(PME) of whom 13 were diagnosed as having MERRF syndrome. Onset 
ranged from 3 to 62 years and within the same family from 4 to 59 years. 
Myoclonus was usually the initial symptom although psychomotor delay 
preceded this in 3 cases. Eight had tonic-clonic seizures which were easy to 
control and only one had intractable seizures. Muscle weakness tended to 
be mild. The progression of the disease was very variable. Cervical lipomas 
developing at around 40 years were noted in one family. Ragged-red fibres 
were seen in 6/8 biopsies. One had non-specific abnormalities and the other 
a normal muscle biopsy but abnormal clumps of mitochondria on skin 
biopsy. 
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Biochemical studies showed normal mitochondrial enzyme activity m 2 
patients, decreased cytochrome c oxidase activity in 1, complex III 
deficiency in 1 and a generalised defect in the other two. 
Positron emission tomography (PET) was carried out in these patients. 
Thirty eight cortical regions were examined. The mean cerebral metabolic 
rate for glucose in MERRF patients was 35 % less than controls and that for 
oxygen 28% less. Cortical blood flow did not differ significantly. These 
findings were compatible with a defect in mitochondrial metabolism. 
Eighty-five EEGs done on these patients showed slowing of background 
activity in 11/13, bursts of bilaterally synchronous delta activity in 10 and 
epileptiform abnormalities in 11. Bilateral massive myoclonus coincided 
with generalised spike and wave discharges in only one patient. The more 
common action myoclonus was not associated with EEG changes. Six of 13 
patients had focal abnormalities and five had occipital spike or sharp waves. 
Slowing was mild to moderate and usually theta frequency. Three patients 
were photosensitive. 
The 2 siblings who were the most severely affected of Berkovic's patients 
had pathological features of Leigh syndrome in addition to the system 
degeneration of MERRF. Their family has since been identified as carrying 
the 8344 tRNA lysine mutation. Apart from classical MERRF and Leigh 
syndromes, this mutation has been associated with adult onset myopathy, 
stroke-like episodes and progressive ophthalmoplegia. Individuals within 
one family may have different presentations owing to mitotic segregation 
and the threshold effect. Other factors as yet unidentified may also play a 
role. 
MELAS 
The patients reported by Pavlakis et al (18) have already been described in 
the historical review. As with MERRF, phenotypic variation due to the 
A3243G tRNA leucine mutation has become evident in recent years. 
In 1983, Rowland (33) reported 11 MELAS patients, all of whom had 
normal early development and onset of symptoms between 4 and 11 years. 
Episodic vomiting associated with migrainous headache was relatively 
common. Recurrent cramping abdominal pain has also been described (34). 
Stroke-like episodes were sometimes delayed until the adult years with 
minor symptoms such as exercise intolerance being the only early indicators 
of disease(35). 
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Sensorineural deafness has been described in a number of patients. The 
identification of the A3243G mutation in families with maternally inherited 
diabetes and no central nervous system (CNS) manifestations has further 
demonstrated the complexity of the clinical syndrome. Some patients with 
MELAS have maternal relatives who have diabetes and/or deafness as the 
only clinical manifestation. 
Fifty patients with MELAS were studied by Sakuta and coworkers (36). 
Clinical characteristics were tabulated with histological and biochemical 
findings. The A3243G mutation was found in 38. Of note is that episodic 
headache and vomiting were found in 86% of patients, convulsions in 81 % , 
visual disturbances in 55 % and transient hemiparesis in only 18 % . These 
four symptom complexes comprised the "stroke-like" episodes. Weakness, 
mental handicap, short stature and deafness were the next most common 
with cardiomyopathy, heart block, ptosis and developmental delay 
occurring in a small number of patients. 
37 /38 (97 % ) had an elevated serum lactate and CSF lactate was elevated in 
all 35 tested. 
Similarly, 37 /38 had ragged-red fibres on muscle biopsy. 
A Canadian study (37) of 10 paediatric patients documented onset between 
2 months and 12 years in their group. None had a positive family history. 
Cortical blindness was common (4/10) and in contrast to the previous study 
7 /10 had hemiparesis, indicating a difference in patient selection. All 
patients developed cognitive deficit. All had increased serum lactate 
(4.5-9.8mM/L) and all had ragged- red fibres. As this was a selected group 
with well documented MELAS it is not surprising that the results were 
uniformly positive. 
LEIGH SYNDROME 
Leigh Syndrome is a well described neuropathological entity (38) with 
characteristic destructive lesions situated symmetrically in subcortical and 
brainstem structures. It was originally described in infants but is now 
known to affect older children and adults as well. Atypical cases with 
cortical involvement have been recognised. Usually three clinical stages 
occur: initial normal development; a second stage of motor regression 
including breathing abnormalities, pyramidal, extrapyramidal or cerebellar 
signs; a final stage which may be prolonged and manifest as extreme 
hypotonia, swallowing difficulties and convulsions. Blood and CSF lactate 
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levels are elevated. Previously the diagnosis was made at autopsy but 
advances in radiology now allow a reasonably confident diagnosis to be 
made prior to this in typical cases (39). 
PYRUV A TE DEHYDROGENASE DEFICIENCY 
Pyruvate dehydrogenase (PDH) deficiency is an important cause of lactic 
acidosis in children. It is a complex enzyme with 3 catalytic components 
and a number of subunits. At least three genetic defects have been identified 
(40). Abnormality of the thiamine pyrophosphate pyruvate decarboxylase 
(El) component is probably the most common (41). The gene for the faulty 
El alpha subunit is located on the X chromosome, Xp22.1. Clinical 
phenotype is characterised by severe, early onset lactic acidosis with 
seizures and apnoeic spells in male infants. Heterozygous females may 
present with neurological symptoms and mild lactic acidosis at a much later 
stage, depending on the pattern of X chromosome inactivation. 
In 30 patients described by Robinson (42) hypotonia and psychomotor 
regression were common. Two patients had recurrent episodes of ataxia 
only. A number were dysmorphic with frontal bossing, wide nasal bridge, 
long philtrum and flared nostrils. Agenesis of the corpus callosum occurred 
in four of the severely affected group. The high number of female infants 
(4/10) with very low levels of enzyme activity is not explained. Genetic 
defects other than that involving the E 1 alpha subunit are nuclear encoded 
and the male/female ratio of affected cases would therefore be expected to 
be equal. 
ALPERSHUTTENLOCHERSYNDROME 
A normal birth and neonatal period are followed by an insidious period of 
developmental delay, failure to thrive and onset of intractable seizures in 
this childhood neuronal degeneration. Liver disease is variable and may 
only present terminally (43). Onset is usually in infancy. EEG findings may 
be quite distinctive with marked slowing of high amplitude mixed with low 
amplitude polyspikes. Pathological findings in the liver consist of 
disorganization with regeneration, fibrosis, bile duct proliferation and 
microvesicular fatty change. Changes in the brain may be extensive with 
neuronal degeneration, astrocytosis, spongiosis and disorganisation. There 
is no biochemical marker for Alpers Syndrome but a mitochondrial 
aetiology has been proposed(44). 
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RADIOLOGY OF MITOCHONDRIAL DISORDERS 
Improved scanning techniques, particularly the advent of magnetic 
resonance imaging (MRI) and functional imaging methods are continuing to 
add to our knowledge of mitochondrial pathology. 
Characteristic of the lesions seen in MELAS is that they cross vascular 
boundaries and are more common in the parieto-occipital regions. The 
process responsible for these radiological appearances remains uncertain. 
They appear as transient, low density regions on CT scan (35), at times 
appearing after an episode of status epilepticus. They may be multifocal at 
onset or involve different regions at different times and they usually involve 
cortical grey matter. Resolution often occurs but is followed by further 
changes. Generalised atrophy and basal ganglia calcification are not 
uncommon. Rare cases of massive focal brain swelling with midline shift 
have been reported ( 45). 
Mathews (46) in 1991, published a report of three MELAS patients who 
had fairly specific MRI abnormalities. Their patients showed laminar 
hyperintense signals on T2 weighted scanning, consistent with oedema or 
focal cortical necrosis. Cortical grey matter and adjacent white matter were 
affected. 
Recent studies of cerebral blood flow in MELAS by Ooiwa (47) were 
published in 1993. Lesions were identified on CT and MRI and were not 
enhanced with gadolinium. Cerebral angiography, when done at the time 
of the stroke-like episodes, showed dilated cortical arteries and focal areas 
of early venous filling. Cerebral blood flow was evaluated by dynamic and 
xenon enhanced CT within 72 hours of onset of the stroke and found to be 
increased in affected areas. Serial studies failed to show an ischaemic area 
at any time throughout the patients' illness. Interpretation of these findings 
suggests that metabolic dysfunction is responsible for the lesions rather than 
ischaemia. 
Evidence of metabolic abnormality has also been demonstrated using 
magnetic resonance spectroscopy (MRS) in four patients with KSS (48). 
Compared with controls they had higher basal lactate levels in the visual 
cortex and did not show transient elevation in response to photic 
stimulation. 
Radiological changes in MERRF are less prominent. Many patients have 
normal scans or exhibit a degree of cerebral atrophy. Low density areas 
within cerebral or cerebellar white matter may be seen. KSS may have 
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similar changes with involvement also of subcortical and brainstem 
structures. Increased signals due to iron or calcium deposition in the basal 
ganglia are also found. 
Positron emission tomography (PET) in MERRF patients measuring the 
cerebral metabolic rate for oxygen and glucose in addition to cerebral 
blood flow (CBF), showed a 30% reduction in these rates when compared 
with controls (49). This was in the presence of normal cerebral blood flow. 
These findings are consistent with a chronically low rate of oxidative 
metabolism. 
Phosphorus magnetic resonance spectra (MRS) can be used to determine the 
concentrations of adenosine triphosphate (ATP), phosphocreatine (PCr), 
and inorganic phosphate in muscle. From these, adenosine diphosphate 
(ADP) levels and the phosphorylation potential of cells can be calculated, 
giving a sensitive indicator of mitochondrial function (50). 
These various functional techniques are becoming increasingly useful m 
mitochondrial research as they allow study of metabolic changes in vivo. 
HISTOPATHOLOGY 
Muscle tissue more than any other has been studied in these patients as it is 
accessible and susceptible to changes in oxidative metabolism. The 
pathological hallmark of mitochondrial disorders is the presence of 
ragged-red fibres when using the Gomori trichrome stain [fig.1]. These are 
fibres with intense red subsarcolemmal staining and a "moth-eaten" 
appearance. They are usually present in Type 1 fibres. They are not 
entirely specific for mitochondrial disease but are very suggestive if present 
in large numbers. Additional non-specific findings on light microscopy 
include atrophy, interstitial fibrosis and fibre hypertrophy ( 16). Ragged-red 
fibres contain more abundant mutated mtDNA and usually lack COX 
activity (29). Overall protein synthesis appears reduced in RRF possibly 
due to a depletion of functional tRNAs. They are commonly found in 
patients with deletions and point mutations affecting tRNA but not in those 
with mutations of structural genes (LHON). 
The histochemical stains, succinate dehydrogenase (SDH) and COX allow 
better interpretation of light microscopy findings. SDH, a Kreb's cycle 
enzyme is a sensitive marker of ragged-red fibres and COX deficiency is an 
indicator of biochemical dysfunction. 
1 6 
Figure 1. Gomori Trichrome stain of a muscle biopsy taken from case 10, 
showing ragged red fibres. 
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More recently, application of immunological techniques has allowed 
comparison of nuclear and mitochondrially encoded protein synthesis in 
individual fibres by using antibodies directed against different subunits of 
the respiratory chain (51,52). 
Electron microscopic findings are variable. They include enlargement of 
mitochondria, bizarre morphology, paracrystalline inclusions, internal 
tubular structures and various abnormalities of cristae formation. These 
findings again are suggestive in the appropriate clinical context but are not 
specific. Similar changes have been induced experimentally by ischaemia 
and toxin exposure. 
A comprehensive review of the neuropathology of mitochondrial disorders 
has recently been published (53). KSS is a multisystem disorder 
characterized by spongiform encephalopathy, neuronal degeneration, 
astrocytosis and demyelination. MERRF tends to select myelinated tracts 
and MELAS has typical features of multifocal necrosis, mineral deposits, 
neuronal degeneration and spongiosis. 
BIOCHEMICAL STUDIES 
These concentrate on defects of the respiratory chain although the broad 
classification of mitochondrial disorders includes pyruvate dehydrogenase 
deficiency and carnitine disturbances amongst others. These assays should 
be done in appropriate circumstances. 
The respiratory chain consists of four multiprotein complexes spanning the 
inner mitochondrial membrane. Electrons are transported along this chain 
through a series of reduction reactions producing oxygen and a large 
amount of energy which is coupled to the formation of ATP. Pyruvate and 
free fatty acids serve as substrates for this process. 
The first of these protein complexes, Complex I (NADH coenzyme Q 
reductase) contains 26 polypeptides, 7 of which are coded for by mtDNA. 
Complex II (succinate coenzyme Q reductase) is coded for by nuclear 
DNA; Complex III (reduced coenzyme Q cytochrome c reductase) has 1 
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mitochondrially coded subunit and Complex IV (cytochrome c oxidase) has 
three. Adenosine triphosphate synthetase (ATPase) or Complex V has two 
subunits coded by mtDNA. 
Many patients have now been reported with defects of respiratory chain 
function arising from genetic mutations in mtDNA. 
Referring to DiMauro's classification (29), MERRF, MELAS, KSS and 
LHON mutations may all cause defects in Complexes I, III and IV. 
Individuals may have partial deficiency of one or all of these enzyme 
systems. The same complexes are affected in maternally inherited deafness, 
diabetes and cardiomyopathy and in congenital fatal myopathy. 
Leigh syndrome has been associated with cytochrome c oxidase (cox)(39) 
and ATPase deficiency, in addition to PDH deficiency (40). COX 
deficiency has also been identified in Alpers syndrome, fatal and benign 
infantile myopathy, CPEO and Menkes disease. 
Correlation between the severity of disease and the degree of biochemical 
deficiency has been shown in several studies but this is not consistent. 
Heteroplasmy may cause equivocal results. Phenotypic variation seems to 
depend in part on the tissue affected and the degree of enzyme deficiency 
but clarification on these issues is still required. 
MITOCHONDRIAL GENETICS 
Refer [fig 2]. 
Mitochondrial deletions: 
Large single deletions are found in KSS, sporadic progressive external 
ophthalmoplegia (PEO) and Pearson Marrow/Pancreas Syndrome. The 
latter consists of a refractory sideroblastic anaemia and exocrine pancreatic 
dysfunction. 
Deletions tend to involve the larger arc of mtDNA between the two origins 
of replication (54). It is thought that these deletions arise during oogenesis. 
Approximately 50% are flanked by direct repeats 5 to 13 base pairs in 
length. The deletions are primarily found in muscle with only very small 
amounts present in fibroblasts and leucocytes. This suggests selection 
against genetically defective mitochondria in rapidly dividing cells. 
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Deletions usually affect a number of tRNAs thereby causing diffuse 
biochemical defects. No clear correlation between the site of the 
biochemical defect and the clinical signs has been established . Patients with 
apparently identical deletions have been found to have different biochemical 
abnormalities and clinical features (54). Where localisation of deficiency 
occurs and the biochemical defect is less than expected it is thought that 
sharing of tRNAs between normal and abnormal genomes within the same 
mitochondrion may occur (55). The proportion of normal to mutant 
mtDNA is therefore important in determining clinical outcome. 
Multiple deletions have been described with an autosomal dominant 
inheritance pattern and in sporadic cases(56).In these cases it seems likely 
that a faulty nuclear gene affects mitochondrial repair mechanisms. 
MERRF and the tRNA lysine mutation: 
The A to G point mutation at bp 8344 m the tRNA lysine gene was 
described by Wallace et al in 1988 (22). This causes a diffuse biochemical 
defect and is heteroplasmic as homoplasmy would be incompatible with 
survival. Normal mtDNA has a protective effect and a decline in protein 
synthesis occurs when levels fall below 15 % . Large changes in phenotype 
can then occur with only small changes in genotype. In the many families 
which have now been reported, correlation between genotype and 
phenotype is not always consistent. The family reported by Graf (57) 
showed 85 % mutant muscle DNA in a mother with marked weakness and 
92 % with normal morphology in her child with minimal symptoms. Age 
may have some bearing on this but does not provide a satisfactory enough 
explanation. 
The A8344G mutation accounts for 80 to 90 % of MERRF cases. A new 
mutation at bp 8356 of the tRNA lysine has recently been described (25). 
MELAS and the tRNA leucine mutation: 
Most patients with typical MELAS have an A3243G mutation in the tRNA 
leucine gene. Some have one at bp3771 in the same gene. The proportion 
of mutant mtDNA is much higher in symptomatic cases than in their 
oligosymptomatic relatives, though it is commonly found even in 
asymptomatic family members. Again the percentage in muscle is much 
higher than in blood and the mutation causes a generalised biochemical 
defect. Diabetes and deafness are often found in family members with the 
mutation and a family with maternally inherited diabetes without 
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Figure 2. Diagramatic representation of mitochondrial DNA demonstrating 





A subgroup of patients with the bp3243 mutation have PEO without stroke 
and this should be considered in those patients with PEO but without 
deletions. 
In conclusion a great deal has been learned about mitochondrial disorders in 
recent years. Diagnosis is becoming easier and it is hoped that further 





AT THE RED CROSS CHILDREN'S WAR MEMORIAL 
HOSPITAL 
A number of children followed up at the Red Cross Children's Hospital 
Neurology Clinic have had unusual presentations associated with 
hyperlactataemia. Many of these had histological changes in skeletal muscle 
suggestive of mitochondrial dysfunction. 
It was proposed to study the clinical, biochemical and histological data of 
these children. Such a data base would give insight into the spectrum of 
clinical pathology in the local population. It would provide documentation 
of unusual cases and critical evaluation of the criteria upon which the 
diagnosis of mitochondrial encephalomyopathy was based. Coordination of 




Criteria for inclusion in the study were: 
a)An unexplained neurological or neuromuscular disease with either (b) or 
(c) 
b)Unexplained elevation in serum lactate > 1,8 mM/L. 
c)Abnormal mitochondrial morphology on either light or electron 
microscopy. 
METHODS 
Children with mitochondrial encephalomyopathies are not readily 
identifiable through the hospital record system as there is no diagnostic 
code for the condition. Cases are therefore coded according to symptoms. 
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The names of children included in the study were supplied by clinicians 
working in the Neurology Service. The children selected were interviewed 
with their parents to obtain a detailed history of the illness and of any 
relevant family history. General, neurological and ophthalmological 
examinations were performed, the latter by arrangement with the 
Department of Ophthalmology. 
Laboratory investigations included the following: 
l .BIOCHEMICAL: 
Electrolytes, renal and liver function tests 
Calcium, magnesium, inorganic phosphate 
Creatine kinase 
Random blood glucose 
Lactate, pyruvate 
Cerebrospinal fluid (CSF) lactate* 
Ammonia* 
Alanine* 
Amino & organic acids* 
Copper, caeruloplasmin* 
Pyruvate dehydrogenase*, pyruvate carboxylase* 
*done on selected patients 
A few patients had further specialised investigations done depending on 
symptomatology. These included arylsulfatase, very long chain fatty acids 
(VLCFA), carnitine levels (1 patient, assay not routinely available), thyroid 




Visual evoked responses (VER) 
Brainstem auditory evoked responses (BAER) 
Nerve conduction studies (NCS) 
Electromyogram (EMG) 
3.RADIOLOGY: 
Computed axial tomography (CT) 




This was done under general anaesthesia. Specimens were taken from the 
deltoid or quadriceps femoris muscle and divided for light and electron 
microscopy. Routine staining included haematoxylin and eosin, the 
modified Gomori trichrome, ATPase, NADH and special stains for lipid in 
some cases. 
RESULTS 
37 children fulfilled the criteria for entrance into the study. Of these 30 
were physically examined by the author, six were unavailable for study and 
1 had died. Data for these latter seven were obtained from hospital files. 
Four other children died during the study period. Causes of death will be 
further discussed. 
The follow up period at Neurology Clinic varied from 2 months to 10 
years, with a mean duration of 3 years 10 months. 
Subjects were between 9 days and 18 years of age with a median age of 7 
years 9 months. Age of onset of symptoms ranged from birth to 8 years. 
Twenty had symptoms before 2 years, eleven between 2 and 6 years and six 
after the age of 6 years. 
All the children who died presented in the first year of life. The oldest age 
at presentation was 8 years. Any child presenting beyond the age of 12 
years would not have been referred to our clinic, but rather to other 
teaching hospitals. 
PERINATAL ABNORMALITIES 
Perinatal complications were common but there was only one documented 
case of asphyxia neonatorum. Three patients had body mass of < 2500 
grams(g) at birth and one was < 1500g. Ten had been born by Caesarean 
Section (CS); 4 of these were elective, 2 for abnormal fetal presentation, 2 
for cephalopelvic disproportion (CPD) and 2 for fetal distress. There were 
2 instrument deliveries and single cases of meconium stained liquor, 
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hypoglycaemia, exchange transfusion and prolonged neonatal jaundice. 
Four infants were hypotonic post delivery and one required ventilation 
(case 12,Table 4). 
Detailed family histories were difficult to obtain in some cases. There were 
2 sibling pairs, one with mental handicap and seizures, the other with 
mental handicap and abnormal eye movements. The latter pair had different 
fathers, supporting maternal inheritance. A number of children had relatives 
with mental handicap, seizures, diabetes mellitus, deafness and muscle 
cramps but maternal inheritance was not clearly demonstrated. 
CLINICAL FINDINGS 
Findings are summarised in Tables [1-4]. Individual cases of interest will 
be discussed in the text. Case numbers refer to Table 4. 
Twenty eight children fulfilled all 3 inclusion criteria. Two had normal 
lactate values with abnormal histopathology and seven did not have a 
muscle biopsy performed. 
Twelve patients had height on the 3rd centile or below. No child was 
under 60 % of expected height. None of the children had clinical evidence 
of retinopathy, deafness or heart block. Renal and endocrine abnormalities 
were also absent. Peripheral neuropathy occurred in two patients. 6 
children had mild dysmorphic features, but none had identifiable syndromes 
or chromosomal abnormalities. 
There were two principal patterns of clinical presentation: encephalopathy 
and myopathy. The diagnosis of encephalopathy was based on loss of motor 
function and or intellectual capacity combined with the appearance of 
abnormal neurological signs. Patients in the myopathic group showed 
weakness with hypotonia or ophthalmoplegia. Thirty patients had 
predominant encephalopathy and seven showed a myopathic picture. Seven 
of those with encephalopathy had global delay and three with myopathy had 
delayed motor milestones. 
ENCEPHALOPATHIC GROUP 
Presenting symptoms in the encephalopathy group were very variable. 
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Six children had stroke-like episodes. Their clinical histories will be 
presented in some detail. 
Case[3 l]: MELAS syndrome. 
This boy had his first episode at 7 years. He had been born prematurely, 
weighing 1300g and was diplegic with mild mental handicap. His mother 
suffers from a psychiatric disorder and after her first pregnancy developed 
sensorineural deafness and 
non-insulin dependant diabetes mellitus. Her older male child is short and 
has some learning difficulties. 
At the onset of his illness he was found unconscious m bed. On 
examination it was noted that he was of short stature and drowsy with 
generally increased tone and reflexes, especially in the lower limbs. As he 
recovered it became apparent that he was cortically blind. CT scan showed 
a low density lesion in the left occipital lobe. Vision recovered slowly over 
several months. He remained well until 9 years when he suddenly became 
acutely confused. EEG showed generalised slowing with temporal sharp 
waves. CSF protein was lg/I and lactate 4.4 mM/L with a serum lactate of 
2. 7mM/L. He recovered within 3 days with mild residual disorientation, 
but 2 weeks later again developed acute confusion, headache and 
photophobia. He had a right sided constructional apraxia with receptive 
and expressive dysphasia and verbal perseveration. At this stage a CT scan 
was done: it showed generalised cortical atrophy. Cerebral angiography 
was normal. On MRI scan a large, left sided low density lesion was seen 
involving the parietal and occipital lobes [fig.3]. Testing DNA from 
circulating white cells showed the bp 3243 tRNA leucine mutation thus 
confirming the diagnosis of MELAS syndrome. 
Recovery from the apraxia and speech disturbances was virtually complete 
a month after the second episode but intellectual function has deteriorated 
smce. 
Family members have not agreed to be tested but it is almost certain that his 
mother carries the mutation and has a milder form of expression. 
Five other children had stroke-like episodes but did not have the typical 
features of MELAS. Only two thus far have had repeated episodes. Their 
details are as follows: 
Case [23] 
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Figure 3. MRI scan of patient 31 (MELAS syndrome) demonstrating low 
intensity signals in the left parietal and both occipital lobes. Atrophy of the right 
occipital lobe is present with ex vacuo dilatation of the posterior horn of the 
right lateral ventricle. 
• 
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This child had intermittent episodes of limb weakness starting at the age of 
2 years. Later speech and swallowing became impaired. He progressed to 
spastic quadriparesis with pseudobulbar palsy and is in a wheelchair at 18 
years. Compared with his motor impairment, intellectual deterioration has 
been slight and growth normal. There is no family history. CT and MRI 
scans have been negative repeatedly. CSF lactate was at the upper limit of 
normal at 1.8 mM/L and serum levels marginally elevated, 2.2 mM/L. EM 
of skeletal muscle showed large mitochondria with whorled cristae. 
Case [29] 
At 2.5 years of age, this patient developed rapid onset of generalised 
weakness and reduced level of consciousness over 5 days. She was 
hypotonic but had brisk reflexes. CSF was normal apart from a lactate of 
4.6 mM/1. Serum lactate was 2. 7 and LIP ratio was 46. CT head was 
normal but on MRI there were low density areas in the basal ganglia, 
external capsule and brainstem. EEG showed marked generalised slowing. 
On muscle biopsy there was evidence of lipid storage but no specific 
mitochondrial changes. She recovered over several weeks but remains 
mentally handicapped. 
Case [22] 
Case [22] developed normally until 2.5 years when he experienced sudden 
onset of right sided weakness followed by rapid progression to complete 
quadriparesis with pseudobulbar palsy. CT and MRI demonstrated large 
confluent plaques of demyelination involving predominantly the centrum 
semiovale, similar to the changes seen in Schilders disease(fig.4). Basal 
ganglia lesions were noted on a follow up scan 3 months after the onset of 
the illness. VLCFA and arylsulfatase levels were normal. CSF had elevated 
lactate at 3.04mM/L. He made good recovery but has residual spasticity 
and mild mental handicap. No subsequent episodes have occurred over 
three years and follow up scans have shown slight resolution of the original 
lesions. 
Case [32] 
This patient developed focal dystonia involving his left leg and later the left 
arm. CT showed a low intensity lesion in the right putamen. MRI 
demonstrated a second area in the left cerebellar peduncle. Serum lactate 
was 2. 9 mM/L,/P ratio 26, CSF lactate done at a later stage was 2.5 
mM/L. There was some peripheral accumulation of stain on the Gomori but 
no RRF. Although seizures were not a feature, the EEG showed 
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Figure 4. MRI Scan of the cranium of case 22 
demonstrates large confluent plaques of demyelination. 
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generalised slowing with a spike and wave paroxysm. Dystonia responded 
to a combination of benzhexol and carbidopa. There was no evidence of a 
vascular or infectious aetiology and Wilson's disease was excluded. 
Two cases had an overlap syndrome with features of both MERRF and 
MELAS. 
Case [15] 
This child deteriorated scholastically at 8 years. His parents are first 
cousins and he has a younger sibling with unilateral ptosis. He developed 
atypical absences with a diffuse epileptiform pattern on EEG. Myoclonic 
jerks, cerebellar signs and visual disturbance with optic atrophy were also 
found. A year after presentation he was admitted with a metabolic acidosis, 
pH 7.07 BE -17 SB 11 and serum lactate 5.9 mM/L with a lactate/pyruvate 
ratio of 53. MRI showed T2 hyperintensity in parietal paraventricular white 
matter as well as in the left occipital horn. CSF lactate measured 2 weeks 
after the acute admission was 3.1 mM/L. Since then there has been slow 
deterioration mentally and poor growth. Generalised, myoclonic and partial 
seizures have all occurred and have been resistant to therapy. On 2 
occasions he has had seizures followed by hemiparesis which has lasted 
several days. Muscle biopsy showed increased subsarcolemmal staining on 
the Gomori and enlarged mitochondria on EM, but the findings were non 
specific. He has had periods of remission lasting up to a year and is 
ambulant 6 years after the onset of his illness. 
Case [19] 
Case 19 also showed a mixed picture. He had apparently uncomplicated 
Haemophilus lntluenzae meningitis at 6 months. At 1 year he developed 
akinetic drop attacks. These were initially infrequent but increased and 
were resistant to therapy with valproate and benzodiazepines. From the age 
of 4 years there was progressive deterioration in his intellectual status and 
he began to walk with a broad base. CT scan was normal. At 8 years he 
was found unconscious in bed following a mild respiratory infection. There 
were no focal neurological signs. He had right sided pneumonia and 
required ventilation for poor respiratory effort. Serum lactate was 6. 8 
mM/L with a lactate/pyruvate ratio of 40. Transaminases and ammonia 
were marginally raised and valproate was discontinued. EEG showed 
marked cortical suppression. On muscle biopsy there was excessive lipid 
accumulation. Repeat CT showed no changes. He remained unrousable for 
a week before making a slow recovery. 
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MERRF-like syndrome 
Apart from cases 15 and 19, three other children(cases 1,3,28) had 
myoclonus, generalised seizures and intellectual deterioration associated 
with elevations in serum lactate levels. Cases 1 and 3 had progressive 
myoclonic epilepsy with short stature, mild dysmorphism and intermittent 
ataxia. Case 28 had progressive myoclonic epilepsy (PME) with poorly 
defined, low amplitude responses on ERG. Other causes of PME were 
excluded. 
Myoclonus was mild and could be controlled with valproate or 
benzodiazepines. None of the three had deafness or a positive family 
history. Cases 1 and 3 had poorly defined VERs and ERGs showed 
increased latency and low amplitude responses in cases 3 and 28. 
Generalised delta activity interspersed with sharp wave activity was also 
found on EEG in cases 1 and 3. Case 28 had intractable seizures and 
records performed during episodes of minor motor status epilepticus 
showed continuous high amplitude spike waves. 
Lactate levels were elevated in all three, independent of ictal activity. 
Lactate/pyruvate (LIP) ratios were 25, 22 and 29 respectively. 
Muscle biopsies showed large, abnormal mitochondria with whorled cristae 
and angular inclusions in case 1. Case 3 showed only minimal changes and 
case 28 did not have a muscle biopsy performed. 
PDH DEFICIENCY 
Two patients were diagnosed as PDH deficient. Case 4 had clinical features 
consistent with a severe defect, with onset of failure to thrive and 
developmental fall off from 6 months of age. She had mild dysmorphic 
features similar to those described in the literature(58). Her course was 
relentlessly progressive with recurrent vomiting, ataxia and increasing 
weakness. She died following an admission to hospital in shock with lactate 
levels of 8.3 and 12 mM/L. 
The other patient, case 36, had a more atypical course. He presented with 
painless, symmetrical distal weakness at three years of age and was found 
to have a sensorimotor neuropathy, confirmed by nerve conduction studies. 
In addition he had limited upward and lateral gaze. Lactate was 10.6mM/L, 
pyruvate 555uM/L and the UP ratio 19. Acidosis was not present although 
there was some respiratory compensation (pH 7.39; CO2 32; BE -3.9; SB 
21). There was gradual progression with increased limb girdle weakness 
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but ambulation was maintained. Ataxia was present, disproportionate to the 
weakness. EMG was indicative of a neuropathy and ERGs were markedly 
reduced bilaterally in the absence of overt retinopathy. This patient 
remained stable enough to attend a school for the physically disabled. 
Growth was normal. 
He presented at 9 years with sudden increase in weakness and ataxia, so 
that he could not walk unaided. He was confused, had staccato speech, 
bilateral ptosis and virtual complete ophthalmoplegia. No signs of infection 
were present. He was commenced on thiamine 600mg daily and was back 
to his previous level of function within 4 days. 
LEIGH SYNDROME 
Case 26 had a clinical course and radiological features compatible with 
Leigh syndrome. She developed normally for the first months of life but at 
6 months became hypotonic, lost head and trunk control and developed 
strabismus. She had intermittent tonic episodes thought to be seizures. Mild 
athetoid movements were present on examination. Three weeks after 
presentation she developed recurrent apnoeic episodes associated with 
generalised slowing on EEG. Her level of consciousness fluctuated. Lactate 
was 2.5mM/L with an LIP ratio of 31. MRI showed symmetrical 
hyperintense lesions on T2 in the midbrain and brainstem. Death occurred 
at 8 months and consent for autopsy was denied. 
ALPERS SYNDROME 
Case 37 also appeared normal initially but developed intractable myoclonic 
seizures and regression at 8 months. A female sibling had died following a 
similar course at 11 months. There were two healthy male siblings and 
there was no history of consanguinity. Her course was relentlessly 
progressive with visual loss, increasing weakness, hypotonia and declining 
level of consciousness. Pronto-temporal atrophy was demonstrated by CT 
and MRI. The EEG showed slow, high amplitude delta interrupted by bursts 
of polyspike and wave activity. A severe burst suppression pattern was 
evident at a later stage. Motor nerve conduction was 43m/second in the 
median nerve and 26m/second in the lateral popliteal. 
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She died soon after the onset of liver failure at 10 months. Eosinophilic 
midzonal necrosis was present in the liver and in the brain neuronal loss 
and gliosis were confined mainly to the calcerine cortex. These histological 
findings were compatible with a diagnosis of Alpers syndrome. 
Of the remaining 16 patients with encephalopathy, 11 had generalised 
seizures and 3 of these were resistant to therapy. 12 had developmental 
regression. Two had delayed milestones from birth. Three had mild 
generalised weakness and three pyramidal tract signs. 
Movement disorders, including ataxia, occurred in 12 children. Eight 
children had ataxia which tended to occur with exacerbations of their 
illness. The pyruvate dehydrogenase (PDH) levels were normal in a child 
with relapsing ataxia as the predominant symptom. Other movement 
disorders included focal dystonia, bilateral ballismus, athetoid movements 
and a paroxysmal dystonic disorder. 
MYOPATHIC GROUP 
Presenting symptoms in the myopathy group were weakness in 4, hypotonia 
in 2 and ophthalmoplegia in one. 
Case 12 presented on day 2 of life with feeding difficulties and tachypnoea. 
Delivery had been normal. She was found to be profoundly hypotonic with 
poor respiratory effort, absent reflexes and a weak cry. Marked 
cardiomegaly was also present. She had a severe mixed respiratory and 
metabolic acidosis. She was intubated, ventilated and given sodium 
bicarbonate. Echocardiography revealed hypertrophy of both ventricles 
without structural malformations. Blood cultures proved negative. 
Metabolic acidosis failed to improve and sodium bicarbonate was infused in 
such quantities that she became hypernatraemic. Blood lactate levels were 
34 mM/L and pyruvate 550 uM/L. The ratio was 60. At this stage a 
diagnosis of congenital lactic acidosis was made. Muscle biopsy showed 
slight accumulation of lipid but no RRF and COX was present. The infant 
died on day 13. 
A brother has myopathic features and there was a paternal uncle who died 
at one year of age with floppiness and cardiomegaly. 
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The other children in the myopathic group had much less severe 
symptomatology. Muscle weakness tended to be mild and proximal, 
involving limb girdles. Power was usually graded 4/5. Three had mildly 
myopathic facies. 
RRF were present in one ( case 10, fig 1), three had increased 
subsarcolemmal accumulations of mitochondria without RRF and two had 
EM changes only. None had paracrystalline inclusions but the patient with 
RRF had rod-like intramitochondrial inclusions. This child had a limb 
girdle myopathy with marked wasting and prominent scapular winging. He ' 
had been floppy since birth and the myopathy was nonprogressive. He had 
mild developmental delay and markedly reduced ERG responses. 
Ophthalmoplegia was not present. CK was 350 u/L and lactate 3.9 mM/L. 
Blood levels of alanine were increased. ECG was normal. Vitamins C and 
K were of no clinical benefit. A maternal cousin had diabetes mellitus and 
another had cerebral palsy. Unfortunately these children were unavailable 
for assessment as they lived some distance away. 
Ophthalmoplegia was unusual and there were no cases of CPEO or KSS. 
One child(case 33) presented with headache and diplopia followed by rapid 
progression to complete external ophthalmoplegia with unilateral ptosis. 
Pupils were unaffected but there was some weakness of neck flexion. An 
edrophonium test, lead levels, and toxin screens were negative. MRI 
showed increased white matter signal intensity on T2 in both cerebral 
hemispheres. Lactate and pyruvate levels were elevated and on muscle 
biopsy there were subsarcolemmal accumulations of abnormal 
mitochondria. This patient recovered fully within a year and has since been 
lost to follow up. 
Recurrent episodes of weakness of abduction of the eyes associated with 
rotary nystagmus occurred in one of the other children and remitted 
spontaneously. 
FATAL CASES 
There were five deaths. Cases 4,(PDH deficiency), 26, (Leigh syndrome), 
37,(Alpers syndrome) and 12(congenital lactic acidosis) have already been 
mentioned. 
The fifth child(case 5) did not have an established diagnosis at the time of 
death. After thriving for the first 6 months of life he too lost head control 
and the ability to sit and became increasingly hypertonic. He was admitted 
with gastroenteritis, hypoglycaemia, metabolic acidosis (pH 7 BE -27 SB 
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6), ketosis and lactic acidosis (6.8 mM/L). CSF lactate was 3.4 mM/L. CT 
head was normal. Muscle biopsy showed enlarged abnormal mitochondria. 
He died following a subsequent similar episode. 
THERAPY 
No controlled trials of therapy were carried out as presentations were 
infrequent, sporadic and variable. Carnitine levels were not routinely 
available but carnitine 100 mg /kg was given to case 5 without 
improvement. It was discontinued after 2 months and the child subsequently 
died. 
Thiamine, riboflavin, vitamins C and K, biotin and citrosoda were given to 
individuals on an ad hoc basis. Apart from the apparent benefit of thiamine 
to patient 36( PDH deficiency), improvement could not be established in 
any of the others. 
BIOCHEMICAL RESULTS 
Electrolytes, urea, creatinine, calcium, magnesium and inorganic phosphate 
were normal in all patients. Blood glucose was low (1.1 mM/L, 1.4 mM/L) 
on two occasions in case 5. Transaminases were also elevated in this case, 
as well as in Case 4 who was receiving sodium valproate, ( < 2x normal in 
both), and in the child who died of Alpers syndrome(case 37). The latter 
also had elevated serum bilirubin and a coagulopathy. 
Creatine kinase was elevated in 4 patients (cases 3, 10, 14,35) with evidence 
of myopathy. The highest level was 432 U/l (15-130 U/l in males). 
Serum lactate was elevated ( > 1. 8 mM/L) in 34/36 children. The mean 
was 3.9 mM/L with a standard deviation (SD) of 4. The highest level 
recorded, 34 mM/L, was in the child with congenital lactic acidosis (case 
12). LIP ratios were > 25 in 23 patients and > 35 in 15. The mean was 
28 with a SD of 10. Four selected patients had elevation of the 
lactate/pyruvate ratio confirmed in cultured fibroblasts, ( Dr P. T. Owen, 
C.Path). 
CSF lactate was raised in 9 of the 13 patients in whom it was measured. 
Serum ammonia was elevated in 9/18 patients, 5 of whom were receiving 
sodium valproate. In no patient was the level greater than twice normal 
(19-57 uM/1). 
4 1 
Table 5. Summary of all serum lactate and pyruvate measurements done. A VG 
is average, STD is standard deviation. 
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NUMBER LACTATE PYRUVATE LACTATE CSF LACTATE 
mM/1 uM/1 PYRUVATE mM/1 
2.40 
l 2.00 78 25 
2 2.90 1.70 
3 4.70 114 41 
3 2.00 
3 2.40 
3 3.60 161 22 
3 2.50 120 21 
3 3.30 164 20 
4 3.10 112 27 4.70 
4 4.60 156 29 3.40 
5 6.80 191 35 
5 4.30 189 23 
6 2.30 112 20 
8 3.40 86 39 
8 1.70 104 16 
7 2.90 78 37 
9 1.50 ND ND 
IO 3.90 442 8 
11 4.60 183 25 .90 
11 2.10 130 16 
12 34.00 500 60 
13 2.90 198 14 
13 4.90 129 37 
14 2.70 75 36 
14 3.10 98 31 
15 5.90 110 53 
16 4.10 159 25 
17 2.30 91 25 
17 4.00 180 22 
18 2.00 84 23 1.10 
18 2.80 154 18 
19 2.80 69 40 
19 2.10 158 13 
19 6.60 164 40 
20 2.10 94 22 
21 2.70 60 45 
22 2.70 146 18 3.00 
23 2.20 98 22 1.80 
24 2.80 84 33 2.00 
25 10.00 
25 5.30 126 42 
25 5.50 113 48 
26 2.30 102 22 3.40 
26 2.50 81 31 
27 3.00 168 18 2.10 
28 2.70 108 25 
28 3.20 109 29 
29 2.70 59 46 4.60 
30 2.70 132 20 1.50 
31 2.70 106 25 4.40 
32 2.60 114 23 2.50 
32 2.90 110 26 
33 2.40 104 23 
34 1.60 72 22 
35 2.00 54 37 
36 10.60 555 19 
37 3.00 131 23 
AVG 3.92 140.67 28.08 2.65 
STD 4.39 97.48 10.82 1.29 
Table 5. 
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Pyruvate Dehydrogenase assay: 
19 patients had PDH assays. Two had activities repeatedly lower than 
controls and one was equivocal. The other 16 assays were normal. 
ELECTROPHYSIOLOGY 
EEG 
Twenty four of 31 patients had abnormalities on EEG. In all, 88 EEGs 
were performed on the children studied over a period of 9 years. 9 children 
had only a single EEG and three of these were normal. 6/7 patients with 
normal EEGs were in the encephalopathy group. 
In the muscle group one child had a generalised seizure disorder(case 9). 
Although she remained seizure free on medication for 18 months, her EEG 
showed diffuse cortical spiking. Another child with muscle weakness and 
mild global delay had focal sharp wave activity (case 35) but no seizures. 
Case 33 had episodic slowing. Three children in this group did not have 
EEGs recorded and the other had a normal EEG. 
Generalised slowing was the most common feature overall, being present in 
11 patients. A further 5 had focal slowing. Sharp or spike and wave 
discharges were superimposed on the background theta or delta frequency 
in some patients. 
Five children had generalised polyspike and wave activity and 8 had focal 
discharges, usually temporal. 
ERG/VER 
12 patients had abnormal ERGs with poorly defined, low voltage responses 
and normal or slightly increased latency. Responses were symmetrical 
except in one patient. No child had clinical retinopathy and the only one 
with visual impairment had early optic atrophy and abnormal visual evoked 
potentials (VEP). The only other child with marked VEP suppression had a 
normal ERG. He was the patient with MELAS(case 31) and recovered 
functional vision following his episode of cortical blindness. 
BAER 
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Brainstem auditory evoked responses (BAER) were abnormal in the patient 
with Leigh Syndrome (case 26). There was increased latency of peaks 3 to 
5 with amplitude attenuation. 
NCS 
Nerve conduction studies (NCS) were performed in 7 children and were 
normal in 5. The patient with Alpers Syndrome (case 37) had slow, low 
voltage responses in the lateral popliteal nerve and slowed conduction. The 
child with PDH deficiency and clinical peripheral sensorimotor neuropathy 
(case 36) also had abnormal studies. 
RADIOLOGY 
CT head scan done on 31 patients showed abnormality in 8. Four showed 
generalised atrophy and one mild frontal atrophy. 
Specific findings on the other three were: 
l.Putaminal hypolucency (case 32). 
2. Extensive attenuation of white matter of internal and external capsules 
(case 22). 
3.Hyperdense lesions in the left internal capsule and globus pallidus (case 
36). 
MRI 
Eleven of the 15 MRI scans done were abnormal. Four had nonspecific 
changes of ventriculomegaly and prominent sulci in the presence of a 
normal CT scan. Depending on accessibility and urgency MRI was usually 
done 2 weeks to several months after CT. 
MRI confirmed the basal ganglia lesion found on CT in case 32 and in 
addition demonstrated a left sided lesion in the cerebellar peduncle. In case 
22 extensive T2 hyperintense signals were seen throughout the white matter 
of the centrum semiovale and in the splenium of the corpus callosum. 
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Follow up scans showed partial resolution but new lesions were 
demonstrated in the basal ganglia several months thereafter. There was no 
accompanying clinical change. 
Five children had abnormalities on MRI not identified by CT scan. They 
were as follows: 
I .Extensive Tl hypointense, T2 hyperintense lesions were present 
symmetrically in the basal ganglia, midbrain, pons and medulla oblongata 
of the child who died after recurrent apnoeic episodes(case 26). These were 
thought consistent with a diagnosis of Leigh Syndrome. 
2.Low intensity areas in the basal ganglia, external capsule and brainstem 
in case 29 who presented with unexplained coma and elevated CSF lactate. 
3.Prominent ventricular system and cerebellar folia as well as T2 
hyperintensity in the paraventricular white matter(case 15). 
4. T2 increased signal intensity in the white matter of both cerebral 
hemispheres in the child with unexplained ophthalmoplegia and no other 
abnormalities (case 33). 
5.A large, left parieto-occipital hypodense lesion in the child with MELAS 
Syndrome (case 31). 
HISTOPATHOLOGY 
Succinate dehydrogenase (SDH) and cytochrome c oxidase (cox) stains 
were not being done by our laboratory at the time of most of these biopsies. 
29 patients had a muscle biopsy performed. Results were normal in 2. The 
patient with MELAS (case 31) did not have a muscle biopsy. 
2 had changes of ragged-red fibres. One was a child with proximal 
myopathy and reduced ERG responses. In addition he had 
intramitochondrial rod-like particles on EM. The other was a mentally 
handicapped child with moderate dysmorphic features of hypertelorism, 
epicanthic folds, flattened occiput and stubby hands. He had partial 
weakness of the right lateral rectus muscle and an elevated serum lactate (4 
mM/1). There did not appear to be any progression of disease during the 4 
years he was followed up. 
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13 biopsies showed focal subsarcolemmal accumulations of mitochondria 
without the typical "moth-eaten" appearance of ragged-red fibres. These 
findings were confirmed on EM. 
EM was normal or nonspecific in 9 specimens. Abnormalities in the 
remainder included; enlarged, bizarrely shaped mitochondria with whorled 
or disorganised cristae, coarse granular aggregates, tubular inclusions and 
subsarcolemmal accumulations of mitochondria. Increased numbers of 
mitochondria and lipid accumulations were present in some specimens. 
These findings were not thought to be artefactual. Paracrystalline inclusions 
were not a feature. 
AUTOPSY FINDINGS 
An autopsy was performed on the child with Alpers Syndrome(case 37). In 
the liver,there was eosinophilic hepatic cell necrosis, mainly in zones two 
and three, and microvesicular fatty change. 
The brain showed non specific degenerative changes in the neurones of the 
dentate nucleus, hippocampal gyrus and brainstem. The calcarine cortex, 
which is characteristically singled out in Alpers Syndrome, was particularly 
affected, with varying degrees of neuronal loss and gliosis. 
MITOCHONDRIAL GENETICS 
Genetic screening for deletions and known point mutations has recently 
become available and was not part of the original study. Thus far one 
patient (case 31) has been identified with the A3243G tRNA mutation and 
MELAS Syndrome as described. 
---oOo---
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DISCUSSION OF FINDINGS 
This study approached mitochondrial metabolic derangements from a 
clinical point of view. It is recognised that there is a broad spectrum of 
presentations and that certain patients with nuclear encoded mitochondrial 
defects do not conform to criteria necessary for the diagnosis of MERRF, 
MELAS or KSS (29). Even patients carrying the mutations responsible for 
these syndromes do not always present with the classical phenotype. Every 
effort had to be made therefore to exclude unrelated conditions. 
The screening methods available identified not only children with potential 
oxidative phosphorylation defects, but also those with other mitochondrial 
enzyme abnormalities such as PDH deficiency. Serum lactate has been 
used as a screening test for mitochondrial disorders in other paediatric 
studies. Tulinius et al(59) selected a level of 2.5 mM/L or above in their 
study of 50 patients. Their laboratory standard values are not reported. 
Patients in the present study who had a level above the upper limit of the 
laboratory normal range (1.8 mM/L), were said to have lactate elevation. 
Venous blood samples were used. Spurious causes of mild elevation such as 
venous stasis, excessive screaming and struggling in younger children were 
avoided. Sedation was given before venesection in problematic cases but 
these were very few. Samples were not taken within 24 hours of a seizure. 
Patients 19 and 37 may have had elevation due to hepatic dysfunction. 
Patient 37 had Alpers Syndrome and patient 19 was on sodium valproate. 
However, both had elevated levels prior to the onset of biochemical liver 
dysfunction. 
The absence of elevated lactate levels cannot be used to exclude 
mitochondrial pathology. Patients with subclinical or even clinically 
manifest disorders may have normal serum lactate or fluctuating levels. To 
detect this group, it may be necessary to take repeated samples, to induce 
elevation by glucose loading or to do an exercise test. 
Glucose loading was introduced by Tulinius in the second half of his study. 
The maximum lactate level in his confirmed group of mitochondrial 
encephalomyopathies was 3.0 mM/L after a load of 1. 75g/kg glucose. This 
compared with a mean fasting value of 3.2 mM/1. In the light of these 
results, the use of this test seems questionable, particularly when the 
biochemical defect is unknown and glucose loading may have potentially 
serious effects. Patients with PDH deficiency may respond particularly 
badly with worsening lactic acidosis. 
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Exercise testing has not been widely reported. It is not always practical to 
perform in the ward situation. Petty, Harding and Morgan-Hughes(60) 
tested 29 adult patients with histologically defined mitochondrial disease. 
They used standard bicycle ergometry and adjusted the load to produce a 
heart rate of 150 beats/minute. Samples were taken before and after 
exercise. The range of lactate values in patients was greater than in controls 
with some patients reaching a value of 10 mM/L. However, there appeared 
to be little significant difference in the mean values. Exercise testing was 
not used in our study as many of the patients were too young or disabled to 
do the test and for practical reasons it is difficult to standardise. 
Histopathological assessment of mitochondrial abnormalities is also not 
without problems. Adequate sampling of muscle and an experienced 
pathologist are essential to proper evaluation. Although RRF are the 
hallmark of these disorders they are not always present nor are they 
specific(61). Cases without RRF have been reported(61). RRF have also 
been found in oligosymptomatic relatives (61) of patients with 
mitochondrial disorders (5/9 in Cialafoni's study). Researchers have found 
them to be absent in a particular specimen and have identified them in a 
different muscle(49). Stadhouders demonstrated that RRF are ragged-red 
only over a limited region of their length(62). As far as possible, clinically 
involved muscle groups should be sampled, bearing in mind that many 
patients have subclinical muscle disease. When present in large numbers 
RRF remain an important indicator of mitochondrial disease. 
More common than RRF are ultrastructural abnormalities. These include a 
variety of nonspecific findings such as mitochondrial enlargement, bizarre 
morphology, subsarcolemmal clustering and inclusions. The paracrystalline 
"parking lot" inclusion is regarded as most typical. Accumulations of 
glycogen and lipid are not infrequently seen. Even when the examiner is 
satisfied about the absence of artefact it remains difficult to decide whether 
changes are due to primary or secondary mitochondrial dysfunction. 
All the limitations listed above were taken into account in the selection and 
critical review of cases included in this study. 
The 36 patients selected formed a clinically heterogenous group. Major 
ethnic groups were equally represented. The early age of onset, under 2 
years in over 50 % , corresponds to that of 0. 8 years in Tulinius' s study. 
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Short stature was a common finding, present in 12/36 patients. 
Abnormalities of growth have frequently been recorded in patients with 
mitochondrial disease. In Egger's study (63) all 13 patients were short and 
reduced growth was noted before the third year in all but two, who 
stopped growing at 5 and 12 years respectively. Growth hormone 
stimulation tests showed normal results in two and abnormal release in 
three. Although treatment with growth hormone increased the yearly 
growth rate, their heights remained below the 3rd centile. 
None of our patients had other causes for short stature: limited energy 
intake was not a factor except in the infant with PDH deficiency who had 
recurrent vomiting and difficulty in feeding. 
Perinatal complications were more common than recorded in other studies 
(63). In part this may reflect the overall higher incidence of perinatal 
morbidity in the local population, attributable to late antenatal booking and 
infrequent clinic attendance, but this is unlikely to be entirely responsible. 
Metabolic factors seem likely to have played a role in the case of the 
mother of patient 31, (MELAS syndrome), who herself had developed 
diabetes and deafness following her first pregnancy. Diabetes alone may 
cause prematurity. To our knowledge, placental factors have not been 
studied in mitochondrial disorders. The lack of perinatal complications in 
the majority of reported cases makes it unlikely that they are a significant 
factor in mitochondrial diseases. 
Although there were three cases with fetal distress, one with asphyxia 
neonatorum and one with borderline hypoglycaemia on day 2, the 
subsequent clinical courses of these patients could not be attributed to 
perinatal problems alone. Patient 20, who had asphyxia neonatorum, was 
moderately mentally handicapped, as was her sister who suffered no 
perinatal insult. She had her first seizure at 10 days, later than those 
usually attributable to hypoxia at birth. The second was at 9 months and 
ataxia with hyperlactataemia was noted in her third year. The other cases 
with perinatal complications were not noted to have any abnormalities until 




The patient with MELAS syndrome,(case 31), had a fairly classical course 
apart from his spastic diplegia. Recurrent stroke-like episodes involving the 
occipital and parietal lobes are characteristic. These episodes often cause 
transient cortical blindness, as in our patient, but constructional apraxia and 
dysphasia have not been widely reported. 
The second insult was extensive, yet virtually complete recovery occurred 
within weeks. There was no evidence of a vascular lesion. Metabolic 
"strokes" seem to have a cumulative effect with gradual deterioration over 
time, yet often surprisingly little residua from individual insults. Neuronal 
death is likely to be far less extensive than that following vascular 
insufficiency due to other causes. 
The exact pathophysiology of these partially reversible lesions remains to 
be defined. Mitochondrial ultrastructural abnormalities have been identified 
in endothelial and smooth muscle cells of blood vessels (64) and some 
authors have suggested that precapillary sphincter dysfunction alters 
autoregulation, thereby inducing ischaemia (65). However, studies of 
cerebral blood flow performed during stroke-like episodes have not 
confirmed this. There has been only a single report of abnormal 
mitochondria in the neurons of the cerebral cortex (66). 
A study of mutant mtDNA content in brain tissue from a MELAS patient 
found that it was generally in excess of 85 % , despite lack of ultrastructural 
changes, indicating again the inconsistent correlation between ultrastructural 
and genetic or biochemical abnormalities (53). 
The serum lactate of patient 31 was only slightly elevated at 2. 7mM/L with 
that in the CSF being 4.4 mM/L and the lactate/pyruvate (LIP) ratio 25. At 
this ratio, NADH and NAO are in equilibrium. With respiratory chain 
dysfunction, an imbalance arises with NADH accumulation driving the 
reaction towards lactate formation. The ratio may have been higher had it 
been measured in CSF. Normalisation of levels may occur fairly rapidly 
following an episode of decompensation. The levels in this case were taken 
several days after the initial insult. CSF levels may remain elevated longer 
as they are independent of serum levels and may more accurately reflect 
cerebral metabolic derangement. 
A muscle biopsy was not performed as the clinical features correlated well 
with the finding of the A3243G mutation and the family were reluctant to 
consent to further investigations. It would almost certainly have shown RRF 
which are present in a high proportion of MELAS patients eg. 87% in 
Goto's (65) study of 40 patients. 
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Determination of specific biochemical defects was not possible. Complex I 
deficiency is most commonly described in association with MELAS, but 
complex IV and combined defects also occur. Some patients with 
documented clinical and genetic features of MELAS show no abnormality 
on currently available biochemical tests of the respiratory chain in muscle. 
Perhaps these would be demonstrated were it possible to test neural tissue. 
The mother of this patient is almost certainly a carrier of the MELAS 
mutation. Diabetes and deafness have now been reported in maternal 
relatives of many MELAS patients. It has as yet not been possible to 
document the extent of the carrier status in this family as members remain 
unwilling to be tested. 
Successful treatment of MELAS with vitamins and coenzymes has been 
reported, but efficacy has been difficult to document. Ihara (66) reported 
successful treatment of a 64 year old woman with MELAS. Her ataxia and 
muscle weakness improved after treatment with coenzyme Q and 
idebenone. EEG showed disappearance of slow wave bursts and dementia 
also improved. Improvement in nerve conduction velocity was documented. 
However, she had not had any stroke-like episodes for several years prior 
to treatment. Other authors (67) also report improvement in patients with 
complex 1 deficiency when treated with riboflavin. Therapy appeared to 
benefit those with myopathy more than those with encephalopathy. There is 
a report of a single patient with MELAS (68) whose previously frequent 
stroke-like episodes (8 admissions/18 months) disappeared for 18 months 
on treatment with nicotinamide and riboflavin. Stroke recurred 7 days after 
cessation of therapy. 
Other researchers have found no benefit from this treatment. Mathews(69) 
studied 16 patients with a variety of mitochondrial disorders over one to 
four 2 month periods of treatment with coenzyme Q, vitamins K and C, 
riboflavin, thiamine and niacin. Response to treatment was monitored by 
exercise testing and phosphorus magnetic resonance spectroscopy (MRS) in 
resting and exercised muscle. No clear improvement could be documented. 
In view of individual cases with reported improvement on vitamin therapy 
and the lack of any alternative treatment, it is probably best to assess the 
clinical response in each patient. Where biochemical diagnosis is not 
available this will remain a process of trial and error but significant side 
effects need not be expected. 
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MELAS was considered a possible diagnosis in four other patients (cases 
23,29,22,32) with stroke-like episodes. 
Patient 23 suffered recurrent stroke-like episodes from the age of 2 years. 
These caused progressive spastic quadriparesis, aphasia, ataxia, internuclear 
ophthalmoplegia and pseudobulbar palsy. No vascular cause was identified. 
CT and MRI scans were repeatedly normal and pathology was assumed to 
involve midbrain and brainstem rather than cortex. Intellectual function was 
largely spared as was somatic growth. In Goto's study (65) of 40 MELAS 
patients, 62 % of those with the 3243 mutation were short and 72 % 
developed mental handicap. 
There was some evidence to support a diagnosis of mitochondrial 
dysfunction in that lactate was elevated in serum and at the upper limit of 
normal in CSF. In addition biopsy showed enlarged mitochondria with 
abnormal cristae and some subsarcolemmal clustering. This is significant 
because muscle abnormalities, other than disuse atrophy, are not usually 
found in CNS disorders. 
On the other hand, the absence of cortical infarcts, dementia, stunted 
growth and RRF makes MELAS an unlikely diagnosis in this case. All that 
can be said is that there is some evidence of mitochondrial dysfunction and 
a lack of any alternative plausible diagnosis. Some comparisons could be 
drawn between this case and cases of alternating hemiplegia of childhood 
in which muscle mitochondrial dysfunction has recently been demonstrated 
(70). 
Three other patients (cases 29,22,32), have had single stroke-like episodes 
only. Follow up has been between 2 and 4 years. 
Patient 29 had a number of features suggestive of a mitochondrial disorder. 
She experienced an unexplained episode of weakness followed by depressed 
level of consciousness. EEG showed generalised slowing and MRI showed 
low density areas suggestive of infarcts in the basal ganglia, external 
capsule and brainstem. These were not as symmetrical as the lesions seen in 
classical Leigh syndrome. CSF lactate was considerably elevated at 4. 7 
mM /L as was the LIP ratio, at 46. No other explanation for the lactate 
elevation or the significantly increased ratio could be found. The 
involvement of the basal ganglia was also suggestive of a metabolic 
disorder. The clinical features could have been caused by encephalitis, but 
there was no fever, leucocytosis or CSF abnormality to substantiate this. 
Toxin ingestion was also a possible explanation but there was no history of 
this and screening tests were negative. 
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She recovered over 4 weeks but has residual moderate mental handicap. 
There has been no progression in the follow up period. A mitochondrial 
disorder is considered highly likely in this patient. A transient disturbance 
of respiratory chain function caused by an unknown toxin is the most 
probable alternative explanation. 
Patient 22 developed progressive quadriparesis with CT and MRI evidence 
of extensive demyelination. CSF lactate was elevated. Clinical recovery 
from initial severe disability occurred with mild residual spasticity. There 
have been no subsequent clinical episodes. The clinical picture was not that 
of one of the degenerative leukodystrophies. Metachromatic and adrenal 
leukodystrophy were excluded biochemically. A post infectious 
demyelination was considered as there had been a recent upper respiratory 
tract infection, but this did not explain the elevated CSF lactate or the 
appearance of new lesions in the basal ganglia several months after the 
initial insult. There was no elevation in CSF protein or cell count. In 
parainfectious disorders the cerebellum and brainstem are more often 
involved than cortical white matter. Multiple cortical lesions have been 
described (71) but none as extensive or confluent as in our patient. Acute 
disseminated encephalomyelitis is usually accompanied by seizures and 
alteration in level of consciousness. Neither were features in this case. 
One of the childhood forms of multiple sclerosis was included in the 
differential diagnosis. These are extremely rare in children under 10 years. 
Schilder disease would be the form most likely in the presence of normal 
CSF protein and confluent plaques on imaging. However in this instance 
the lesions did not enhance with contrast as described in Schilder disease. 
Abnormalities in lactate metabolism have not been described in this 
disorder. 
A recessive familial leukoencephalopathy is another possible diagnosis but 
there was no history of consanguinity to support this. It thus seems most 
feasible that an occult metabolic error became apparent under conditions of 
increased stress, provided perhaps by a viral infection. 
Extensive demyelination is not a characteristic finding in mitochondrial 
disorders. It is unusual in MELAS and when present in KSS and MERRF, 
occurs in conjunction with areas of spongy degeneration (53). There has 
been a recent report of a set of dizygotic twins with non-progressive 
leukoencephalopathy and large , confluent T2 hyperintense lesions on MRI 
(72). One twin had myopathy and the other myopathy with myoclonic 
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epilepsy. The 3243 MELAS mutation was detected in the latter, at lower 
levels than occur in patients with MELAS. The mutation could not 
definitely be linked to the demyelination or the muscle pathology. 
Patient 32 with focal dystonia also provided diagnostic difficulties. The 
clinical course and CT findings were not those of classical torsion dystonia. 
There were not the obvious diurnal fluctuations of Segawa disease. Other 
causes of putaminal hypolucency including arterial infarcts and viral 
infection could not be excluded but there was no evidence to support their 
presence. 
Examination of the patient's retina showed hyperaemia, some tortuosity and 
dilatation of vessels and some haemorrhages. Visual acuity was 6/9. Similar 
findings have been described in patients with Leber's Hereditary Optic 
Neuropathy (LHON). Some families with LHON have been reported with a 
hereditary spastic dystonia and putaminal necrosis (73). Onset was between 
5 and 9 years with normal early development and a stationary or slow 
progressive course. The dystonia in these patients was associated with 
spasticity and often involved facial and bulbar muscles with dysarthria. 
Bilateral or unilateral putaminal hypodensity was present. This disorder has 
been described in only three families. This patient has no family history of 
blindness but this unusual form of LHON nevertheless deserves 
consideration in the differential diagnosis. 
PDH DEFICIENCY 
Two patients (cases 4, 36) in this study had documented PDH deficiency. 
Neither had a positive family history. The majority of documented defects 
of PDH involve the El alpha subunit which is coded by DNA on the X 
chromosome. This El component is dependant on a thiamine pyrophosphate 
cofactor. A predominance of males has been reported in some studies but 
there have also been many females affected to varying degrees. The 
explanation for this could be that the pattern of X inactivation within tissues 
leads to variable expression, or alternatively that the defect lies in one of 
the other subunits of PDH. The El beta and E3 components have been 
mapped to chromosomes 3 and 7 respectively (74). 
Skin fibroblast activities of PDH do not always correlate with the clinical 
severity. The degree of activity varies in different tissues so that fibroblast 
levels may not be representative of brain PDH activity. This cannot be 
explained by heteroplasmy as PDH is nuclear encoded. It is possible that 
different tissues recognise and degrade mutant proteins variably, but this 
remains to be proved. 
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The specific defects in these two patients could not be defined, but pyruvate 
decarboxylase(El) deficiency is probably the most likely. The second case, 
36, was similar to one described by Evans (75), which also showed 
episodic weakness, ataxia and impaired ocular motility of acute onset 
following an infection. Recovery started after 2 weeks and took 3 months. 
Marked growth retardation was present. Unusual was that patient 36 
subsequently thrived and made a remarkably rapid recovery from a very 
disabled state. Although it seems reasonable to attribute this at least in part 
to thiamine, this could not be substantiated biochemically. 
The ERG findings in this patient are also unusual. They are reproducible 
and are too marked to be artefactual. No visual impairment is evident nor 
any clinical retinopathy. The possibility of dual pathology has been 
considered but the presence of a second rare inherited disorder seems 
unlikely. Screening for mitochondrial deletions has been negative. 
He will be maintained on thiamine and a high fat low carbohydrate diet. 
LEIGH SYNDROME 
The patient with Leigh Syndrome had a typical course with normal early 
development, followed by regression, seizures, choreoathetoid movements 
and respiratory abnormalities. MRI showed symmetrical T2 hyperintense 
lesions in the midbrain, pons and medulla. PDH deficiency was not 
excluded in this patient. Complex l and cytochrome c oxidase deficiency 
have also been documented in Leigh syndrome but the resulting phenotypes 
are indistinguishable. The COX defect would appear different to that 
documented in MELAS in that inheritance follows a recessive pattern, 
indicating a nuclear defect rather than one in mitochondrial DNA (76). 
There is a recent report of an 18 year old patient with features of MERRF 
but without RRF, who developed Leigh syndrome, confirmed at autopsy 
(77). The 8344 mutation, characteristic of MERRF, was found in high 
percentages: blood: 81 %; skeletal muscle: 99%, ocular muscle:97%, 
cerebellum:97%, cerebral cortex: 97%, heart: 97%, liver:99% and kidney: 
98%. The patient's normal mother had 72% in blood and probably more in 
other tissues. This case demonstrates a number of interesting features: 
a) the correlation of the 8344 MERRF mutation with Leigh Syndrome. 
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b) the absence of RRF in a patient with features of MERRF and a very high 
proportion of mutant DNA in muscle. Severe cytochrome c oxidase 
deficiency was documented histochemically and there was evidence of 
increased mitochondrial mass. Other patients reported with MERRF have 
had only 50 or 60 % mutant mtDNA in muscle. This suggests that factors 
other than mitochondrial proliferation must influence the development of 
RRF. 
c) the absence of liver pathology in the presence of 99% mutated mtDNA. 
It is to be expected that these levels would exceed the threshold for disease 
expression and again as yet unknown factors must play a role. 
Patients with Leigh syndrome have also been found to carry the NARP 
mutation. There is thus increasing evidence that the pathological features of 
Leigh Syndrome may coexist with severe phenotypic expression of several 
different mtDNA mutations(80). 
ALPERS SYNDROME 
A recessive pattern of inheritance was likely in the child who died of Alpers 
Syndrome (case 37). A sibling had died of a similar illness. There was no 
known consanguinity and no relatives were affected. The biochemical and 
genetic basis of Alpers Syndrome is unknown but some authors have 
recently suggested a mitochondrial aetiology (78). It may become evident 
that different mutations are responsible for a similar phenotype, as in Leigh 
Syndrome. 
The clinical course of the patient was very typical with initial normal 
development followed by failure to thrive, intractable seizures, regression, 
and ultimately liver failure. 
Eosinophilic midzonal hepatic necrosis was present as reported (43). 
Valproate therapy, which was used in this case, has divided opinion on the 
aetiology of liver damage (43). In Harding's series of 32 patients (43), 
probably the largest group reviewed, valproate therapy appeared unrelated 
to outcome. Two pairs of siblings in this study exhibited identical hepatic 
pathology in the presence and absence of the drug. 
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Selective involvement of the calcarine cortex, as documented at autopsy in 
patient 37, is characteristic of Alpers syndrome (43). It is generally 
accepted that cerebral damage in these cases is not solely as a result of 
uncontrolled seizure activity or hepatotoxicity (43). The aetiology of this 
form of hepatocerebral degeneration remains to be elucidated. 
MERRF-LIKE SYNDROME 
Patients 1, 3 and 28 had many of the features of MERRF syndrome but 
without RRF. Patient 3, in particular, had progressive myoclonic epilepsy, 
ataxia, weakness, dementia short stature and pyramidal tract signs. 
Myoclonus is often the presenting feature in MERRF. It tends to be 
stimulus induced and may occur with or independently of ictal discharges. 
It may be difficult to control. The three patients in this study had mild 
myoclonus which was not stimulus induced; it was frequently but not 
always associated with ictal episodes and could be controlled with 
benzodiazepines. Ataxia worsened during episodes of seizure exacerbation. 
Anticonvulsant toxicity was not found to be responsible. Hyperlactataemia 
was consistently present in all three patients, independant of seizure 
activity. LIP ratios were elevated, suggestive of respiratory chain 
dysfunction. 
Neither patient 1 nor patient 3 had RRF. Cases of MERRF who carry the 
8344 mutation but who lack RRF have been described. Graf and coworkers 
(57) reported a mother and her two symptomatic children in whom only 
the mother had RRF, despite a higher proportion of mutant DNA in the 
children's biopsies. Findings such as these have yet to be explained. A 
possible explanation may be found in the role played by mutations induced 
by aging. 
Silvestri found a high correlation between the clinical phenotype of MERRF 
and the 8344 mutation when screening 150 patients with suspected 
mitochondrial encephalomyopathy (24). Sixteen of 150 patients had the 
mutation. Eleven had MERRF, 2 had other mitochondrial encephalopathies, 
2 had limb girdle myopathy and 1 had PEO. This would indicate that if 
only limited numbers can be screened, those patients with the characteristic 
phenotype and RRF are most likely to be positive. 
Despite the absence of RRF, patient 1 had significant abnormalities on EM 
of biopsied muscle. 
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There was insufficient evidence to identify these patients positively as 
having MERRF syndrome although they had a number of characteristic 
features. They may belong to a nuclear encoded subgroup of mitochondrial 
myopathies but biochemical confirmation of respiratory chain derangement 
is needed to clarify this diagnosis. 
Two patients had overlap syndromes with features of MERRF and 
MELAS: 
Patient 22 had ataxia, optic atrophy, ophthalmoplegia and an intractable 
seizure disorder with myoclonus and stroke-like episodes. He had one 
admission with severe lactic acidosis. The features were highly suggestive 
of mitochondrial disease. His parents were first cousins indicating that he 
may have a nuclear encoded defect. Juvenile neuronal ceroid lipofuscinosis 
(NCS) was considered but this could not explain the lactic acidosis and 
there was no histological evidence to support this diagnosis. In addition he 
has had periods of remission from seizures and remains ambulant 7 years 
after the onset of symptoms. 
Patient 19 had normal early development followed by atonic attacks, mental 
deterioration and an episode of unexplained coma. Features in favour of 
mitochondrial disease were lactic acidosis and an elevated LIP ratio. Lipid 
accumulation was present on biopsy. There was mild elevation of 
transaminases but no hypoglycaemia. He had been receiving valproate 
therapy for almost 4 years before his admission with reduced level of 
consciousness. It seems unlikely that his state could have been due to 
toxicity, but the drug was nevertheless discontinued. CT scan showed no 
specific features and MRI was not performed. Lesions may have been 
identifiable had this been done but there were no focal signs and he 
recovered to his former level of function. 
The remainder of the encephalopathy group had nonspecific findings. 
Seizure disorders and developmental regression were the most common. 
Generalised seizures were most frequent. 
Movement disorders occurred in four patients. The child with ballismus 
(case 11) had prolonged depression in consciousness following a first 
episode of seizures. She was from a country area and may have become 
hypoxic during status epilepticus. PDH activity was normal. Ballismus 
resolved but she suffered residual moderate mental handicap. 
59 
There was no adequate explanation for the clinical signs, lactate elevation 
and EM changes found in the other patients. Mitochondrial disease could 
neither be confirmed nor excluded. 
MYOPATHY GROUP 
The infant with congenital lactic acidosis (case 12) almost certainly had 
mitochondrial dysfunction. The presence of cardiomyopathy is not typical 
of PDH deficiency or fatal infantile lactic acidosis caused by cytochrome c 
oxidase deficiency as described by DiMauro (79). Both benign and fatal 
infantile mitochondrial myopathy show COX negative fibres which this 
patient did not have. Defective NADH oxidation has been demonstrated in 
an infant with a similar disorder but without cardiomyopathy (80). 
The family history suggests that there may have been an affected paternal 
uncle. This reduces the likelihood of the maternally inherited myopathy and 
cardiomyopathy which has been described (81). Dilated cardiomyopathy 
has been described with multiple deletions (82). The defect in our patient 
would appear to be nuclear encoded. 
The clinical features of patient 10 were compatible with a diagnosis of 
congenital myopathy except that he had subclinical retinopathy. The 
histological and biochemical features suggest a mitochondrial abnormality 
with RRF and hyperlactataemia, 3.9 mM/L. Histological features of other 
congenital myopathies were not present. The rod-like inclusions were 
intramitochondrial. 
Mitochondrial myopathies seldom present in the neonatal period and when 
they do, are usually indicative of a severe defect. However, forms of 
mitochondrial myopathy which undergo spontaneous improvement have 
been reported and in general there is such a degree of phenotypic 
heterogeneity that mitochondrial myopathy remains the most acceptable 
diagnosis in this patient. 
Patient 33 had a relatively acute onset of progressive ophthalmoplegia 
involving all external ocular muscles. This resolved over several months. 
Lactate was 2.4 mM/L. Initially he was thought to have extensive RRF but 
review of the biopsy showed subsarcolemmal mitochondrial accumulations 
only. A variant of the Miller Fisher syndrome was considered but there was 
no ataxia, reflexes were normal and CSF protein was not elevated. Areas of 
demyelination in the cerebral hemisphere are not a feature of Miller Fisher 
syndrome. 
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There was no history of snake bite. Some local varieties of snake venom 
cause cranial nerve paralysis. 
A mitochondrial disorder could not be excluded as there was some evidence 
in the muscle biopsy to support this diagnosis. Recurrent episodes of 
ophthalmoplegia may occur with PDH deficiency but there are usually other 
signs. This patient was lost to follow up. It is to be expected that he would 
have returned to the hospital had he suffered further episodes. The 
explanation for his symptoms remains unknown. 
FATAL CASES 
No diagnosis could be made in patient 5 who died. The marked lactic 
acidosis was in keeping with mitochondrial disturbance. The presence of 
large quantities of ketones reduced the likelihood of carnitine deficiency. 
Recurrent episodes of decompensation occurred so an extraneous toxic 
cause was also unlikely. 
BIOCHEMISTRY 
The mean lactate level in these patients was greater than twice the upper 
limit of normal and was above Tulinius' mean of 3.0 mM/L. There was a 
large SD indicating wide scatter. Only 2 patients had levels lower than 1.8 
mM/L; these were 1.5 and 1.6 mM/L. Neither had the test repeated or was 
stressed. 
The mean LIP ratio was also elevated with a large SD. Values ranged from 
8, in patient 10 with a lactate of 3.9 mM/L and pyruvate of .442 mM/L, to 
60 in the infant with congenital lactic acidosis (case 12). 
CSF lactate was elevated in 70% of patients in whom it was measured. This 
is significant as CSF lactate is metabolised independently of serum lactate 
and probably better reflects cerebral metabolism. 
These results are useful as a guide but cannot be considered in isolation, as 




The generalised slowing on EEG found in 35 % of patients is characteristic 
of metabolic dysfunction. One was a postictal record and is not included. 
Focal and generalised epileptic discharges were common. Tulinius 
documented similar findings in his patients but to our knowledge there has 
not been detailed reporting of EEG changes in paediatric patients with 
mitochondrial pathology. 
A careful study in 13 adult MERRF patients showed slowing in 85 % with 
bursts of synchronous frontal delta activity in 10/13 (83). 70% had bursts 
of spike and wave or polyspike and wave activity and 6 had focal 
discharges. Action and intention myoclonus were not clearly related to EEG 
discharges. 
Twelve of our patients had abnormal electroretinograms without clinical 
evidence of retinopathy. Technical error was excluded as far as possible. In 
most reported series, ERG has been done when there is already evidence of 
retinopathy. Its usefulness as a screening test has not been established, but 
it is reasonable to assume that it may be a more sensitive indicator of 
dysfunction than the presence of overt retinal changes. These cases will be 
followed to monitor any progression. 
RADIOLOGY 
Relevant findings have been discussed in conjunction with case histories. 
MRI was more sensitive than CT scan particularly when visualising basal 
ganglia, midbrain and brainstem structures. A direct comparison could not 
be made owing to the time lapse between scans. 
Specific imaging features have been described m MELAS and Leigh 
syndrome but more than 50 % of MERRF patients and many of those with 
KSS have normal imaging or nonspecific changes (84). 
IDSTOPATHOLOGY 
Only two of the patients studied had RRF. More might have been expected 
in a study of patients with mitochondrial disease. The succinate 
dehydrogenase stain (SDH), a more sensitive marker of mitochondrial 
proliferation than the Gomori, was not used routinely. Only two of the 29 
patients who were studied had normal biopsies; the rest showed 
subsarcolemmal accumulations of mitochondria or mitochondrial 
ultrastructural changes. It cannot be proved that these arose as a result of 
primary mitochondrial dysfunction, but such a high incidence of skeletal 
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muscle abnormalities would not be anticipated in a group of children with 
mainly CNS pathology. Hypoxia could be documented as a possible 
contributing factor in one child only. No extraneous toxins were identified. 
In Tulinius's study, 17/20 children with confirmed mitochondrial 
encephalomyopathy had ultrastructural changes in mitochondria at biopsy. 
Only 7 showed typical RRF. Two had MERRF, two had MELAS and two 
had KSS. The other child had features of MERRF but without myoclonus. 
Three children with normal muscle biopsies had complex I deficiency. This 
illustrates that although there is a good correlation between RRF and the 
classical MERRF, MELAS, KSS phenotypes there may well be a larger 
group of patients with as yet unidentified genetic defects or partial 
expression of known defects who do not have RRF. 
CONCLUSIONS 
This study was undertaken to provide a comprehensive data base on patients 
with suspected mitochondrial disease seen at the Red Cross Childrens' 
Hospital. Only children with neuromuscular features were examined and 
there may well be others whose presenting complaints prompted referral to 
the cardiology or endocrine clinics. 
The study identified 30 patients with an encephalopathic clinical picture and 
7 with a myopathic picture. A mitochondrial disorder was positively 
identified in 5 cases: MELAS syndrome (case 31), PDH deficiency (cases 
4,36), Leigh syndrome (case 26) and Alpers syndrome (case 37). In the 
remainder, clinical, biochemical and histological data available were 
suggestive of mitochondrial pathology but this could not be confirmed. As 
the features in many cases were not typical of MERRF, MELAS or KSS 
and clear matrilineal inheritance was not evident, it is likely that some of 
these children fall into DiMauro's mitochondrial encephalomyopathy or 
myopathy groups with complex I or Ill defects. These are nuclear encoded 
and the genes have not been identified. They manifest with a broad 
spectrum of clinical features similar to those found in our patients; 
dementia, seizures, ataxia, retinopathy, myopathy and movement disorders. 
An impression was gained that mitochondrial disorders may be 
underdiagnosed at the hospital. Ability to confirm this impression was 
limited by the lack of specialised investigations. In order to investigate 
selected patients further, biochemical assay of respiratory chain function is 
necessary. This would provide a better idea of the prevalence of these 
disorders. Such a screen would need to be specific, accessible and 
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inexpensive. The feasibility of measuring ATP production in permeabalised 
fibroblasts by a fluorometric method is currently being investigated by the 
author. 
Establishment of an assay to measure total, free and esterified carnitine in 
serum and muscle would be of value in excluding disorders due to primary 
carnitine metabolic problems and in diagnosing secondary carmtme 
deficiency caused by respiratory chain dysfunction (85) or valproate 
therapy. 
There are many neurological disorders that remain as yet unexplained in 
terms of their genetic and biochemical aetiology. The discovery of the 
"25th chromosome", mtDNA, has provided researchers and clinicians with 
some insight into the mechanisms underlying a small group of these 
diseases. Since genetic screening for deletions and point mutations in 
mtDNA can now be performed locally, the diagnosis can be confirmed in 
certain cases. 
Much of the challenge still remains. As appropriate treatment in any 
medical problem relies on an accurate diagnosis, it is hoped that further 
research will not only aid the clinician in making the correct diagnosis but 
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